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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE OF MAINE,
Plaintiffs,
v.

XXL IMPRESSIONS LLC, a limited liability
company, also d/b/a BETTER HEALTH
NUTRITIONALS,
JEFFREY R. POWLOWSKY, individually
and as an owner and officer of XXL
IMPRESSIONS LLC,
J2 RESPONSE L.L.P., a limited liability
partnership, also d/b/a J2 RESPONSE,
JUSTIN BUMANN, individually
and as partner o f J2 RESPONSE L.L.P.,
JUSTIN STEINLE, individually and as a
partner o f J2 RESPONSE L.L.P.,
SYNERGIXX, LLC, a limited liability
company, also d/b/a CTF MEDIA,
CHARLIE R. FUSCO, individually
and as an owner and officer o f SYNERGIXX,
LLC,
RONALD JAHNER, and
BRAZOS MINSHEW a/k/a SAMUEL BRANT,
Defendants.

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

Case No. 1:17-cv-0006-NT

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANTS J2 RESPONSE L.L.P.
d/b/a J2 RESPONSE, JUSTIN
BUMANN, and JUSTIN STEINLE

The following is submitted pursuant to Section XIX o f the above-captioned Order, under
penalty o f perjury.

1. Each Defendant must: (a) identify the primary physical, postal, and email address and
telephone number as designated points of contact; (b) identify all of that Defendant’s
businesses by all of their names, telephone numbers, and physical, postal, email, and
Internet addresses; (c) describe the activities of each business, including the goods and
services offered, the means of advertising, marketing, and sales, and the involvement of
any other Defendants (which Individual Defendants must describe if they know or
should know due to their own involvement); (d) describe in detail whether and how
that Defendant is in compliance with each Section of this Order; and (e) provide a copy
of each Order Acknowledgment obtained pursuant to this Order, unless previously
submitted to Plaintiffs.

® J2 (no update)
0

Justin Bumann (new business)
a) (no update)
b) JJC Walker Partners, LLC: 321 E Main, Ste. 206, Bozeman, MT, 59719
Phone: None
Email: None
Website: None
c) JJC Walker Partners, LLC: Marketing Services

s

Justin Steinle (new business)
a) (no update)
b) JJC Walker Partners, LLC: 321 E Main, Ste. 206, Bozeman, MT, 59719
Phone: None
Email: None
Website: None
c) JJC Walker Partners, LLC: Marketing Services

2. Individual Defendants must: (a) identify all telephone numbers and all physical,
postal, email, and Internet addresses, including all residences; (b) identify all
business activities, including any business for which such Defendants perform
services whether as employees or otherwise and any entity in which such
Defendants have any ownership interest; and (c) describe in detail such Defendants’
involvement in each such business, including title, role, responsibilities,
participation, authority, control, and any ownership.
® Justin Bumann
a) (no update)
b) JJC Walker Partners, LLC: Ownership Interest
c) JJC Walker Partners, LL: Partner - provides services to support the
business - Ownership Interest

Justin Steinie
a) (no update)
b) JJC Walker Partners, LLC: Ownership Interest
c) JJC Walker Partners, LL: Partner - provides services to support the
business —Ownership Interest

Justin Bumann
July 3,2019

Justin Steinie
July 3,2019

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

)
)
) Case No. 1:17-cv-00067-NT

Plaintiffs,

)

)

v.

)
)
) ACKNOWLEDGMENT OF RECEIPT
) OF FINAL JUDGMENT & ORDER BY
) DEFENDANT RONALD JAHNER
)
)
)
)
)
)

XXL IMPRESSIONS LLC a limited liability
company, also d/b/a BETTER HEALTH
NUTRITIONALS,
JEFFREY R. POWLOWSKY, individually
and as an owner and officer of XXL
IMPRESSIONS LLC,
J2 RESPONSE L.L.P., a limited liability
partnership, also d/b/a/ J2 RESPONSE,

)
)

)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P., )

)
JUSTIN STEINLE, individually and as a
partner of J2 RESPONSE L.L.P,

)
)

SYNERGIXX, LLC, a limited liability
company, also d/b/a CTF MEDIA,

)

)
)

)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX, )
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS M INSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
)
)
)
Plaintiffs,
)
)
v.
)
)
)
)
XXL IMPRESSIONS LLC a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
)
JEFFREY R. POWLOWSKY, individually
)
and as an owner and officer o f XXL
)
IMPRESSIONS LLC,
)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a/ J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

Case No. l:17-cv-00067-NT

ACKNOWLEDGMENT OF RECEIPT
OF FINAL JUDGMENT & ORDER BY
DEFENDANTS SYNERGIXX, LLC,
also d/b/a CTF MEDIA, and CHARLIE
R. FUSCO

DocuSign Envelope ID: 36FD851F-C341-4FB6-BB9E-3A929E49D65A

The undersigned defendants acknowledge, under penalty of perjury, that they have
received a copy o f the Final Judgment & Order entered against them in this case (Dkt. 42) by the
District Court for the District of Maine on September 13, 2017.
ACKNOWLEDGED this

day of

10/ 6/2017

,2017.

>— ■DocuSigned by:

(J x j A x l fuse*
be fendtffilAGharlie R. Fusco, individually

and on behalf of Synergixx, LLC
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE OF MAINE,
Plaintiffs,
v.

XXL IMPRESSIONS LLC, a limited liability
company, also d/b/a BETTER HEALTH
NUTRITIONALS,
JEFFREY R. POWLOWSKY, individually
and as an owner and officer of XXL
IMPRESSIONS LLC,
J2 RESPONSE L.L.P., a limited liability
partnership, also d/b/a J2 RESPONSE,
JUSTIN BUMANN, individually
and as partner of J2 RESPONSE L.L.P.,
JUSTIN STEINLE, individually and as a
partner of J2 RESPONSE L.L.P.,
SYNERGIXX, LLC, a limited liability
company, also d/b/a CTF MEDIA,
CHARLIE R. FUSCO, individually
and as an owner and officer of SYNERGIXX,
LLC,
RONALD JAHNER, and
BRAZOS MIN SHEW a/k/a SAMUEL BRANT,
Defendants.

)
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Case No. l:17-cv-0006-NT

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANTS J2 RESPONSE L.L.P.
d/b/a J2 RESPONSE, JUSTIN
BUMANN, and JUSTIN STEINLE

The following is submitted pursuant to Section XIX o f the above-captioned Order, under
penalty o f peijury.

1. Each Defendant must: (a) identify the primary physical, postal, and email address and
telephone number as designated points of contact; (b) identify all of that Defendant’s
businesses by all of their names, telephone numbers, and physical, postal, email, and
Internet addresses; (c) describe the activities of each business, including the goods and
services offered, the means of advertising, marketing, and sales, and the involvement of
any other Defendants (which Individual Defendants must describe if they know or
should know due to their own involvement); (d) describe in detail whether and how
that Defendant is in compliance with each Section of this Order; and (e) provide a copy
of each Order Acknowledgment obtained pursuant to this Order, unless previously
submitted to Plaintiffs.

•

J2 (no update)

•

Justin Bumann (new business)
a) (no update)
b) Metrics Media Group LLC: 547 S 7th St., #305, Bismarck ND 58504
Phone: 866-477-4420
Email: contactus@metiicsmg.com
Website: www.metricsmediagroup.com
c) Metrics Media Group LLC: Service: Business Development for
Marketing Services Companies
Individual Defendant Justin Bumann knows Justin Steinle as
Partner o f Metrics Media Group LLC.

•

Justin Steinle (new business)
a) (no update)
b) Metrics Media Group LLC 547 S 7th St., #305, Bismarck ND 58504
Phone: 866-477-4420
Email: contactus@metricsmg.com
Website: www.metricsmediagroup.com
c) Metrics Media Group LLC: Service: Business Development for
Marketing Service Companies
Individual Defendant Justin Steinle knows Justin Bumann as
Partner o f Metrics Media Group LLC.

2. Individual Defendants must: (a) identify all telephone numbers and all physical,
postal, email, and Internet addresses, including all residences; (b) identify all
business activities, including any business for which such Defendants perform
services whether as employees or otherwise and any entity in which such
Defendants have any ownership interest; and (c) describe in detail such Defendants’
involvement in each such business, including title, role, responsibilities,
participation, authority, control, and any ownership.

Justin Bumann
a) (no update)
b) Metrics Media Group LLC : Ownership Interest
c) Metrics Media Group LLC : Managing Partner - provides daily services
to support the business services of Business Development for Marketing
Service Companies - Ownership Interest

Justin Steinle
a) (no update)
b) Metrics Media Group LLC: Ownership Interest
c) Metrics Media Group LLC: Managing Partner - provides daily services
to support the business services of Business Development for Marketing
Service Companies - Ownership Interest

/Jtistin Bumann
September 19, 2018

September 19,2018

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
)
)
) Case No. l:17-cv-00067-NT
Plaintiffs,
)
)
v.
)
)
)
XXL IMPRESSIONS LLC, a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
) BRAZOS MINSHEW
) ACKNOWLEDGMENT OF
JEFFREY R. POWLOWSKY, individually
) RECEIPT OF STIUPLATED
and as an owner and officer of XXL
) FINAL JUDGMENT & ORDER
IMPRESSIONS LLC,
) AS TO BRAZOS MINSHEW
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

I, Brazos Minshew, acknowledge receipt of a copy of the Stipulated Final Judgment &
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
)
)
)
Plaintiffs,
)
)
)
v.
)
)
)
XXL IMPRESSIONS LLC, a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
)
JEFFREY R. POWLOWSKY, individually
)
and as an owner and officer of XXL
)
IMPRESSIONS LLC,
)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

Case No.

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANT BRAZOS MINSHEW,
A/K/A SAMUEL BRANT
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Plaintiffs, the Federal Trade Commission (“FTC” or “Commission”) and the State of
Maine, as represented in this matter by the Office of the Attorney General of Maine (“Maine
AG”) (“Plaintiffs”), filed a Complaint for Permanent Injunction and Other Equitable Relief
against Defendants pursuant to Section 13(b) of the Federal Trade Commission Act (“FTC Act”),
15 U.S.C. § 53(b), and pursuant to Section 209 of the Maine Unfair Trade Practices Act (“Maine
UTPA”), Me . Rev . Stat . tit. 5, § 209, to obtain permanent injunctive relief, rescission or
reformation of contracts, restitution, the refund of monies paid, disgorgement of ill-gotten
monies, and other equitable relief for Defendant’s acts or practices in violation of Sections 5(a)
and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, and in violation of Section 207 of the Maine
UTPA, M e . Rev . S tat. tit. 5, § 207, in connection with the labeling, advertising, marketing,
distribution, and sale of products that purported to provide relief from back and joint pain and to
prevent or mitigate cognitive decline.
The Commission, the State of Maine, and Defendant Brazos Minshew, a/k/a Samuel
Brant (“Defendant Minshew”) stipulate to the entry of this Final Judgment and Order for
Permanent Injunction and Other Equitable Relief as to Defendant Minshew.
FINDINGS
1.

This Court has jurisdiction over this matter.

2.

The Complaint charges that Defendant Minshew participated in deceptive acts or

practices in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, and in
violation of Section 207 of the Maine UTPA, Me . Rev . Stat. tit. 5, § 207, in connection with the
advertising, marketing, distribution, and sale of dietary supplements that purported to provide
pain relief and to prevent or mitigate cognitive decline.

2
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Defendant Minshew neither admits nor denies any o f the allegations in the

Complaint, except as specifically stated in this Order. Defendant Minshew admits the facts
necessary to establish jurisdiction only for purposes of this action.
4.

Defendant Minshew waives any claim that he may have under the Equal Access

to Justice Act, 28 U.S.C. § 2412, concerning the prosecution of this action through the date of
this Order, and agrees to bear his own costs and attorney fees.
5.

Defendant Minshew and Plaintiffs waive all rights to appeal or otherwise

challenge or contest the validity of this Order.
DEFINITIONS
For the purpose of this Order, the following definitions apply:
1.

“Defendant” means Brazos Minshew, a/k/a Samuel Brant.

2.

“Covered Product” means any Dietary supplement, Food, or Drug, including but

not limited to CogniPrin.
3.

“Dietary supplement” means:
A.

any product labeled as a dietary supplement or otherwise represented as a
dietary supplement; or

B.

any pill, tablet, capsule, powder, softgel, gelcap, liquid, or other similar
form containing one or more ingredients that are a vitamin, mineral, herb
or other botanical, amino acid, probiotic, or other dietary substance for use
by humans to supplement the diet by increasing the total dietary intake, or
a concentrate, metabolite, constituent, extract, or combination of any
ingredient described above, that is intended to be ingested, and is not

3
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represented to be used as a conventional food or as a sole item of a meal
or the diet.
4.

“Drug” means: (1) articles recognized in the official United States

Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) articles intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in humans or other animals; (3) articles (other
than food) intended to affect the structure or any function of the body of humans or other
animals; and (4) articles intended for use as a component of any article specified in (1), (2), or
(3); but does not include devices or their components, parts, or accessories.
5.

“Essentially Equivalent Product” means a product that contains the identical

ingredients, except for inactive ingredients (e.g., binders, colors, fillers, excipients), in the same
form and dosage, and with the same route of administration (e.g., orally, sublingually), as the
Covered Product; provided that the Covered Product may contain additional ingredients if
reliable scientific evidence generally accepted by experts in the field indicates that the amount
and combination of additional ingredients is unlikely to impede or inhibit the effectiveness of the
ingredients in the Essentially Equivalent Product.
6.

“Food” means: (1) any article used for food or drink for humans or other

animals; (2) chewing gum; and (3) any article used for components of any such article.
7.

“Including” means including but not limited to.

8.

“Person” means a natural person, an organization, or other legal entity, including

a corporation, partnership, sole proprietorship, limited liability company, association,
cooperative, or any other group or combination acting as an entity.

4
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I.

PROHIBITED REPRESENTATIONS: MITIGATION OF COGNITIVE DECLINE,
MEMORY IMPROVEMENT, AND DISEASE CLAIMS
IT IS HEREBY ORDERED that Defendant, Defendant’s officers, agents, employees,
and attorneys, and all other persons in active concert or participation with any of them, who
receive actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product, are permanently restrained and enjoined from making, or assisting others in
making, expressly or by implication, including through the use of a product name, endorsement,
depiction, or illustration, any representation, that, in humans, such Covered Product:
A.

Reverses, mitigates, or prevents cognitive or mental decline;

B.

Improves memory;

C.

Restores lost memory capacity; or

D.

Cures, mitigates, or treats any disease;

unless the representation is non-misleading and, at the time of making such representation, they
possess and rely upon competent and reliable scientific evidence substantiating that the
representation is true. For purposes of this Section, competent and reliable scientific evidence
shall consist of human clinical testing of the Covered Product, or of an Essentially Equivalent
Product, that is sufficient in quality and quantity based on standards generally accepted by
experts in the relevant disease, condition, or function to which the representation relates, when
considered in light of the entire body o f relevant and reliable scientific evidence, to substantiate
that the representation is true. Such testing must be: (1) randomized, double-blind, and placebocontrolled; and (2) conducted by researchers qualified by training and experience to conduct

5
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such testing. Persons covered by this section have the burden of proving that a product satisfies
the definition of Essentially Equivalent Product.
II.
PROHIBITED REPRESENTATIONS: OTHER HEALTH-RELATED CLAIMS
IT IS FURTHER ORDERED that Defendant, Defendant’s officers, agents, employees,
and attorneys, and all other persons in active concert or participation with any of them, who
receive actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product, other than a representation covered under the Section of this Order titled
Prohibited Representations: Mitigation O f Cognitive Decline, Memory Improvement, And
Disease Claims, are permanently restrained and enjoined from making, or assisting others in
making, expressly or by implication, including through the use of a product name, endorsement,
depiction, or illustration, any representation about the health benefits, safety, performance, or
efficacy o f any Covered Product, unless the representation is non-misleading, and, at the time of
making such representation, they possess and rely upon competent and reliable scientific
evidence that is sufficient in quality and quantity based on standards generally accepted by
experts in the relevant disease, condition, or function to which the representation relates, when
considered in light of the entire body of relevant and reliable scientific evidence, to substantiate
that the representation is true.
For purposes of this Section, competent and reliable scientific evidence means tests,
analyses, research, or studies (1) that have been conducted and evaluated in an objective manner
by experts in the relevant disease, condition, or function to which the representation relates;
(2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that
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are randomized, double-blind, and placebo-controlled human clinical testing of the Covered
Product, or of an Essentially Equivalent Product, when such experts would generally require
such human clinical testing to substantiate that the representation is true. Persons covered by this
section have the burden of proving that a product satisfies the definition of Essentially
Equivalent Product.
III.
PROHIBITED REPRESENTATIONS REGARDING TESTS, STUDIES,
OR INGREDIENTS
IT IS FURTHER ORDERED that Defendant, Defendant’s officers, agents, employees,
and attorneys, and all other persons in active concert or participation with any of them, who
receive actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product are permanently restrained and enjoined from misrepresenting, in any manner,
expressly or by implication, including through the use of any product, endorsement, depiction, or
illustration:
A.

That any Covered Product is clinically proven to restore or improve memory, or
mitigate cognitive decline;

B.

That the performance or benefits of any Covered Product are scientifically
proven or otherwise established; or

C.

The existence, contents, validity, results, conclusions, or interpretations of any
test, study, or other research.
IV.
FDA-APPROVED CLAIMS

IT IS FURTHER ORDERED that nothing in this Order prohibits Defendant,
7
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Defendant’s officers, agents, employees, and attorneys, or all other persons in active concert or
participation with any of them, from:
A.

For any drug, making any representation that is approved in labeling for such drug
under any tentative final or final monograph promulgated by the Food and Drug
Administration, or under any new drug application approved by the Food and
Drug Administration; and

B.

For any product, making a representation that is specifically authorized for use in
labeling for such product by regulations promulgated by the Food and Drug
Administration pursuant to the Nutrition Labeling and Education Act of 1990 or
permitted under Sections 303-304 of the Food and Drug Administration
Modernization Act of 1997.
V.
PROHIBITED REPRESENTATIONS
AS AN EXPERT ENDORSER

IT IS FURTHER ORDERED that Defendant, Defendant’s officers, agents, employees,
and attorneys, and all other persons in active concert or participation with any of them, who
receive actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product are permanently restrained and enjoined from making, directly or by
implication, any representations as an expert endorser, including, but not limited to, the
representations covered by the Sections of this Order titled Prohibited Representations:
Mitigation O f Cognitive Decline, Memory Improvement, And Disease Claims (Section I) and
Prohibited Representations: Other Health-Related Claims (Section II), above, unless he
possesses the represented expertise and he possesses and relies upon:
8
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Competent and reliable scientific evidence required for the particular
representation, as set forth in Sections I and II, above; and

B.

An actual exercise of the represented expertise, in the form of an
evaluation or test of such product conducted and evaluated in an objective
manner and which is generally accepted in the relevant profession to yield
accurate and reliable results.
VL
COOPERATION WITH FTC AND MAINE

IT IS FURTHER ORDERED that Defendant must fully cooperate with representatives
of the Commission, the Maine AG, and any of their representatives in this case and in any
investigation related to or associated with the transactions or the occurrences that are the subject
of the Complaint. Defendant must provide truthful and complete information, evidence, and
testimony. Defendant must appear for interviews, discovery, hearings, trials, and any other
proceedings that a representative of the Commission or the Maine AG may reasonably request
upon 5 days’ written notice, or other reasonable notice, at such places and times as a
Commission or Maine AG representative may designate, without the service of a subpoena.
VII.
ORDER ACKNOWLEDGMENTS
IT IS FURTHER ORDERED that Defendant acknowledge receipt of this Order within
7 days o f entry of this Order. Such acknowledgment must be sworn under penalty of perjury and
must be submitted to the Commission and the State of Maine upon receipt of this Order.
Additionally,
A.

For 10 years after entry of this Order, Defendant must, for any

9
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business involved in the sale or marketing of any Covered Product that Defendant
is the majority owner or controls directly or indirectly, must deliver a copy of this
Order to:
1.

All principals, officers, directors, and LLC managers and members;

2.

All employees, agents, and representatives who participate in the labeling,
advertising, marketing, distribution, or sale of any Covered Product or
service; and

3.

Any business entity resulting from any change in structure as set forth in
the Section titled Compliance Reporting.

Delivery must occur within 7 days of entry of this Order for current personnel. For all
others, delivery must occur before they assume their responsibilities.
B.

From each individual or entity to which Defendant delivered a copy of this
Order, Defendant must obtain, within 30 days, a signed and dated
acknowledgment of receipt of this Order.
VIII.
COMPLIANCE REPORTING

IT IS FURTHER ORDERED that Defendant make timely submissions to the
Commission and to the Maine AG:
A.

60 days after entry of this Order, Defendant must submit a compliance
report, sworn under penalty of perjury:
1.

Defendant must: (a) identify the primary physical, postal, and
email address and telephone number as designated points o f contact,
which Plaintiffs’ representatives may use to communicate with Defendant;
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(b) identify all of Defendant’s businesses by all of their names, telephone
numbers, and physical, postal, email, and Internet addresses; (c) describe
the activities of each business, including the goods and services offered,
the means of advertising, marketing, and sales, and the involvement of any
other Defendant (which Defendant must describe if he knows or should
know due to his own involvement); (d) describe in detail whether and how
Defendant is in compliance with each Section of this Order; and
(e) provide a copy of each Order Acknowledgment obtained pursuant
to this Order, unless previously submitted to Plaintiffs.
2.

Additionally, Defendant must: (a) identify all telephone numbers and all
physical, postal, email, and Internet addresses, including all residences;
(b) identify all business activities, including any business for which
Defendant performs services whether as an employee or otherwise and any
entity in which Defendant has any ownership interest; and (c) describe in
detail Defendant’s involvement in each such business, including title, role,
responsibilities, participation, authority, control, and any ownership.

B.

For 10 years after entry of this Order, Defendant must submit a compliance
notice, sworn under penalty of perjury, within 14 days of any change in the
following:
1.

Defendant must report any change in: (a) any designated point of contact;
(b) the structure of any corporation or any entity that Defendant has any
ownership interest in or control, directly or indirectly, that may affect
compliance obligations arising under this Order, including: creation,
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merger, sale, or dissolution o f the entity or any subsidiary, parent, or
affiliate that engages in any acts or practices subject to this Order.
2.

Additionally, Defendant must report any change in: (a) names, including
aliases or fictitious names, or residence addresses; or (b) titles or roles in
any business activity, including any business for which Defendant
performs services whether as an employee or otherwise and any entity in
which Defendant has any ownership interest, and identify the name,
physical address, and any Internet address of the business or entity.

C.

For a period of 10 years, Defendant must submit to the Commission and
the Maine AG notice of the filing of any bankruptcy petition, insolvency
proceeding, or similar proceeding by or against Defendant within 14
days of its filing.

D.

Any submission to the Commission or the Maine AG required by this Order
to be sworn under penalty of perjury must be true and accurate and comply with
28 U.S.C. § 1746, such as by concluding: “I declare under penalty of perjury
under the laws of the United States of America that the foregoing is true and
correct. Executed on: ________ ” and supplying the date, signatory’s full name,
title (if applicable), and signature.

E.

Unless otherwise directed by a Commission representative in writing, all
submissions to the Commission pursuant to this Order must be emailed to
DEBrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to:
Associate Director for Enforcement, Bureau of Consumer Protection, Federal
Trade Commission, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580.
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The subject line must begin: FTC v. XXL Impressions LLC et al., and the number
X____________ .
F.

Unless otherwise directed by a Maine AG representative in writing, all
submissions to the Maine AG pursuant to this Order must be sent by
overnight courier (not the U.S. Postal Service) to: Office of the Attorney General
of Maine, Consumer Protection Division, 111 Sewall Street, 6th Floor, Augusta,
ME 04330. The subject line must begin: Order in re State o f Maine v.
XXL Impressions LLC et al. and must identify the Court and docket number of
this Order as ordered by the Court.
IX.
RECORDKEEPING

IT IS FURTHER ORDERED that in connection with the sale of any Covered Product,
Defendant must create certain records for 10 years after entry of the Order, and retain each such
record for 5 years. Specifically, Defendant must, for any business that Defendant is a majority
owner or controls, directly or indirectly, must create and retain the following records:
A.

Accounting records showing the revenues from all goods or services sold, all
costs incurred in generating those revenues, and the resulting net profit or loss;

B.

Personnel records showing, for each person providing services, whether as an
employee or otherwise, that person’s: name; address; telephone numbers; job title
or position; dates of service; and (if applicable) the reason for termination;

C.

Complaints and full or partial refund requests, whether received directly or
indirectly, such as through a third party, and any response;

D.

All records necessary to demonstrate full compliance with each provision of this
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Order, including all submissions to the Commission and the Maine AG; and
E.

A copy of each unique advertisement or other marketing material.
X.
COMPLIANCE MONITORING

IT IS FURTHER ORDERED that, for the purpose of monitoring Defendant’s
compliance with this Order:
A.

Within 14 days of receipt of a written request from a representative of
the Commission or the Maine AG, Defendant must: submit additional
compliance reports or other requested information, which must be sworn under
penalty of perjury; appear for depositions; and produce documents for inspection
and copying. Plaintiffs are also authorized to obtain discovery, without further
leave of court, using any of the procedures prescribed by Federal Rules of Civil
Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45, and 69.

B.

For matters concerning this Order, the Plaintiffs are authorized to
communicate directly with Defendant. Defendant must permit Plaintiffs’
representatives to interview any employee or other person affiliated with
Defendant who has agreed to such an interview. The person interviewed may
have counsel present.

C.

Plaintiffs may use all other lawful means, including posing, through their
representatives, as consumers, suppliers, or other individuals or entities, to
Defendant or any individual or entity affiliated with Defendant, without the
necessity of identification or prior notice. Nothing in this Order limits the
Commission’s lawful use of compulsory process, pursuant to Sections 9 and 20 of
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the FTC Act, 15 U.S.C. §§ 49, 57b-l. Nothing in this Order limits the
Maine AG’s lawful use of compulsory process, pursuant to section 211 of the
Maine UTPA, M e . Rev . S tat. tit. 5, § 211. Defendant hereby consents to the
disclosure by the Maine AG to any law enforcement agency and any
representative of the State of Maine o f any material or information produced by
Defendant pursuant to section 211 of the Maine UTPA, whether produced before
or after the date of this Order.
D.

Upon written request from a representative of the Commission or the State of
Maine, any consumer reporting agency must furnish consumer reports concerning
Defendant Minshew, pursuant to Section 604(1) of the Fair Credit Reporting Act,
15 U.S.C. §1681b(a)(l).

Ill
III
III
III
III
III
III
III
III
III
III
III
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XI.
RETENTION OF JURISDICTION
IT IS FURTHER ORDERED that this Court shall retain jurisdiction of this matter for
purposes of construction, modification, and enforcement of this Order.
IT IS SO ORDERED this 10th day of March, 2017.

/s/ Nancy Torresen____________
United States Chief District Judge

IT IS SO STIPULATED this 15 day of February, 2017.
DAVID C. SHONKA
Acting General Counsel
/s/ James A. Pruntv
James A. Prunty
David P. Frankel
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, D.C. 20580
Telephone: 202-326-2438, 2812
Facsimile: 202-326-3259
Email: jprunty@ftc.gov
dfrankel @ftc.gov
Attorneys for Plaintiff
FEDERAL TRADE COMMISSION
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IT IS SO STIPULATED this 15 day of February, 2017.
JANET T. MILLS
Attorney General, State of Maine

/s/ Brendan F.X. O ’Neil
Brendan F.X. O’Neil
Assistant Attorney General
Office of the Attorney General o f Maine
6 State House Station
Augusta, Maine 04333-0006
Telephone: 207-626-8842
Facsimile: 207-624-7730
Email: brendan.oneil@maine.gov

IT IS SO STIPULATED this 10 day of February, 2017.

/s/ Brazos Minshew
Defendant Brazos Minshew
Pro Se
2126 S. 48th Street
Coolidge, Arizona 85128
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
)
)
)
Plaintiffs,
)
)
v.
)
)
)
XXL IMPRESSIONS LLC, a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
)
)
JEFFREY R. POWLOWSKY, individually
)
and as an owner and officer of XXL
)
IMPRESSIONS LLC,
)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

Case No. l:17-cv-00067-NT

JEFFREY R. POWLOWSKY
AND XXL IMPRESSIONS LLC
ACKNOWLEDGMENT OF
RECEIPT OF STIUPLATED
FINAL JUDGMENT & ORDER
AS TO JEFFREY R. POWLOWSKY
AND XXL IMPRESSIONS LLC

I, Jeffrey R. Powlowsky, acknowledge receipt of a copy o f the Stipulated Final Judgment
& Order entered in this case against me and XXL Impressions LLC on March 10,2017.

behalf of

2

i

iwlowsky, individually
Impressions LLC ( /
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
)
)
)
Plaintiffs,
)
)
v.
)
)
)
XXL IMPRESSIONS LLC, a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
)
)
JEFFREY R. POWLOWSKY, individually
)
and as an owner and officer of XXL
)
IMPRESSIONS LLC,
)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

Case No.

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANTS XXL IMPRESSIONS
LLC, also d/b/a BETTER HEALTH
NUTRITIONALS, and JEFFREY R.
POWLOWSKY

Case l:1 7 -cv-0 0 0 6 7 -N T

Docum ent 25

Filed 03/10/17

Page 3 of 37

P a g e lD # :2 9 4

FINDINGS
1.

This Court has jurisdiction over this matter.

2.

The Complaint charges that Defendants participated in deceptive acts or practices

in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, the
Telemarketing and Consumer Fraud and Abuse Prevention Act (“Telemarketing Act”), 15
U.S.C. §§6101-6108, the FTC’s Trade Regulation Rule entitled “Telemarketing Sales Rule”
(“TSR”), 16 C.F.R. Part 310, the Electronic Fund Transfer Act (“EFTA”), 15 U.S.C. §§ 16931693r, and its implementing Regulation E, 12 C.F.R. § 1005.10, and Section 207 of the Maine
UTPA, M e . Re v . Stat . tit. 5, § 207, in connection with the labeling, advertising, marketing,
distribution, and sale of products purported to provide pain relief and to prevent or mitigate
cognitive decline.
3.

Defendants neither admit nor deny any of the allegations in the Complaint, except

as specifically stated in this Order. Defendants admit the facts necessary to establish jurisdiction
only for purposes of this action.
4.

Defendants represent that they have ceased all sales of the products at issue in this

Complaint, and all continuity orders of such products.
5.

Defendants waive any claim that they may have under the Equal Access to Justice

Act, 28 U.S.C. § 2412, concerning the prosecution of this action through the date of this Order,
and agree to bear their own costs and attorney fees.
6.

Defendants and Plaintiffs waive all rights to appeal or otherwise challenge or

contest the validity of this Order.
DEFINITIONS
For the purpose of this Order, the following definitions apply:
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The disclosure must comply with these requirements in each medium
through which it is received, including all electronic devices and face-toface communications;

G.

The disclosure must not be contradicted or mitigated by, or inconsistent
with, anything else in the communication; and

H.

When the representation or sales practice targets a specific audience, such
as children, the elderly, or the terminally ill, “ordinary consumers”
includes reasonable members of that group.

2.

“Close proximity” means that the disclosure is very near the triggering

representation. For example, a disclosure made through a hyperlink, pop-up, interstitial, or other
similar technique is not in close proximity to the triggering representation.
3.

“Corporate Defendant” means XXL Impressions LLC and its successors and

assigns.
4.

“Covered Product” means any Dietary Supplement, Food, or Drug, including but

not limited to FlexiPrin and CogniPrin.
5.

“Defendants” means Individual Defendant and Corporate Defendant,

individually, collectively, or in any combination.
6.

“Dietary supplement” means:
A.

any product labeled as a dietary supplement or otherwise represented as a
dietary supplement; or

B.

any pill, tablet, capsule, powder, softgel, gelcap, liquid, or other similar
form containing one or more ingredients that are a vitamin, mineral, herb
or other botanical, amino acid, probiotic, or other dietary substance for use
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“Material connection” means any relationship that materially affects the weight

or credibility o f any Endorsement and that would not reasonably be expected by consumers.
13.

“Negative Option Feature” means, in an offer or agreement to sell or provide

any good, program, or service, a provision under which the consumer’s silence or failure to make
an affirmative action to reject goods or services, or to cancel the agreement, is interpreted by the
seller or provider as acceptance of the offer.
14.

“Person” means a natural person, an organization, or other legal entity, including

a corporation, partnership, sole proprietorship, limited liability company, association,
cooperative, or any other group or combination acting as an entity.
15.

“Preauthorized Electronic Fund Transfer” as defined by the Electronic Fund

Transfer Act, 15 U.S.C. § 1693a(10), means an electronic fund transfer authorized in advance to
recur at substantially regular intervals.
I.

TWENTY YEAR BAN ON DIRECT RESPONSE MARKETING OF FOOD, DIETARY
SUPPLEMENTS, OR DRUGS FOR WHICH A HEALTH BENEFIT IS CLAIMED
IT IS HEREBY ORDERED that Defendants, whether acting directly or indirectly, are
hereby restrained and enjoined, for 20 years from the date of this Order, from advertising,
marketing, promoting, offering for sale, or distributing through Direct Response Marketing, or
assisting in the advertising, marketing, promoting, offering for sale, or distributing through
Direct Response Marketing, any Covered Product for which a health benefit is claimed
expressly or by implication. Provided, however, subject to the Sections of this Order entitled
Prohibited Representations: Pain Relief, Cartilage Rebuilding, Cognitive Decline, Memory
Improvement, and Disease Claims; Prohibited Representations: Other Health-Related Claims;
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B.

Provides relief from back pain;

C.

Reduces the need for medication;

D.

Helps rebuild damaged joints or cartilage;

E.

Reverses, mitigates, or prevents cognitive or mental decline;

F.

Improves memory;

G.

Restores lost memory capacity; or

H.

Cures, mitigates, or treats any disease;

P agelD #: 300

unless the representation is non-misleading and, at the time o f making such representation, they
possess and rely upon competent and reliable scientific evidence substantiating that the
representation is true. For purposes of this Section, competent and reliable scientific evidence
shall consist of human clinical testing o f the Covered Product, or of an Essentially Equivalent
Product, that is sufficient in quality and quantity based on standards generally accepted by
experts in the relevant disease, condition, or function to which the representation relates, when
considered in light of the entire body of relevant and reliable scientific evidence, to substantiate
that the representation is true. Such testing shall be: (1) randomized, double-blind, and placebocontrolled; and (2) conducted by researchers qualified by training and experience to conduct
such testing. In addition, all underlying or supporting data and documents generally accepted by
experts in the field as relevant to an assessment of such testing as described in the Section
entitled Preservation of Records Relating to Competent and Reliable Human Clinical Tests or
Studies must be available for inspection and production to Plaintiffs. Persons covered by this
Section shall have the burden of proving that a product satisfies the definition of Essentially
Equivalent Product.
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such human clinical testing to substantiate that the representation is true. In addition, when such
tests or studies are human clinical tests or studies, all underlying or supporting data and
documents generally accepted by experts in the field as relevant to an assessment of such testing
as set forth in the Section entitled Preservation of Records Relating to Competent and Reliable
Human Clinical Tests or Studies must be available for inspection and production to Plaintiffs.
Persons covered by this Section have the burden of proving that a product satisfies the definition
of Essentially Equivalent Product.
IV.
PROHIBITED REPRESENTATIONS REGARDING TESTS, STUDIES,
OR INGREDIENTS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product are hereby permanently restrained and enjoined from misrepresenting, in any
manner, expressly or by implication, including through the use of any product name,
endorsement, depiction, or illustration:
A.

That any Covered Product is clinically proven to rebuild joint cartilage, reduce
back or joint pain, reduce stiffness, or reduce inflammation;

B.

That any Covered Product is clinically proven to restore or improve memory, or
mitigate cognitive decline;

C.

That the performance or benefits of any Covered Product are scientifically
proven; or
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All documents referring or relating to recruitment; randomization; instructions,
including oral instructions, to participants; and participant compliance;

C.

Documents sufficient to identify all test participants, including any participants
who did not complete the test, and all communications with any participants
relating to the test; all raw data collected from participants enrolled in the test,
including any participants who did not complete the test; source documents for
such data; any data dictionaries; and any case report forms;

D.

All documents referring or relating to any statistical analysis of any test data,
including, but not limited to, any pretest analysis, intent-to-treat analysis, or
between-group analysis performed on any test data; and

E.

All documents referring or relating to the sponsorship of the test, including all
communications and contracts between any sponsor and the test’s researchers.

Provided, however, the preceding preservation requirement shall not apply to a reliably
reported test, unless the test was conducted, controlled, or sponsored, in whole or in part by:
(1) any Defendant; (2) any Defendant’s officers, agents, representatives, or employees; (3) any
other person or entity in active concert or participation with any Defendant; (4) any person or
entity affiliated with or acting on behalf of any Defendant; (5) any supplier of any ingredient
contained in the product at issue to any of the foregoing or to the product’s manufacturer; or
(6) the supplier or manufacturer of such product.
For purposes o f this Section, “reliably reported test” means a report of the test has been
published in a peer-reviewed journal, and such published report provides sufficient information
about the test for experts in the relevant field to assess the reliability of the results.
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VIII.
PROHIBITED REPRESENTATIONS
RELATED TO ADVERTISING FORMAT
IT IS FURTHER ORDERED that Defendants and their officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order by personal service or otherwise, whether acting directly or indirectly,
in connection with the advertising, marketing, promotion, offering for sale, sale, or distribution
of any good or service, are hereby permanently restrained and enjoined from misrepresenting
that paid commercial advertising is independent programming, including independent,
educational programming, or an objective news report.
They are further permanently restrained and enjoined from presenting any radio
advertisement fifteen (15) minutes in length or longer or intended to fill a time slot of fifteen (15)
minutes in length or longer that does not state in the same language as the predominant language
used in the advertisement, in a Clear and Conspicuous manner within the first thirty (30) seconds
of the commercial and immediately before each presentation of ordering instructions for the
good or service, the following disclosure:
“THE PROGRAM YOU ARE LISTENING TO IS A PAID
ADVERTISEMENT FOR [THE PRODUCT, PROGRAM, OR SERVICE].”

For the purpose of this provision, the presentation of a telephone number, mailing address, or
website through which listeners may obtain more information or place an order for the
product, program, or service shall be deemed a presentation of ordering instructions so as to
require the stating o f the disclosure provided herein.
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The total cost to purchase, receive, or use the good or service, including shipping,
handling, processing, and any additional financial obligations that may be
incurred as a result of accepting the free product, service, or offer;

C.

The timing or manner of any charge or bill;

D.

Any material restrictions, limitations, or conditions to purchase, receive, or use
the good or service; and

E.

Any material aspect of the performance, efficacy, nature, or central characteristics
of the good or service.
XI.
REQUIRED DISCLOSURES

IT IS FURTHER ORDERED that, in connection with the advertising, marketing,
promotion, offering for sale, sale, or distribution of any good or service, Defendants and their
officers, agents, and employees, and all other persons in active concert or participation with any
of them who receive actual notice of this Order, whether acting directly or indirectly, are
permanently restrained and enjoined from:
A.

Failing to Clearly and Conspicuously disclose, or assisting others in failing to
Clearly and Conspicuously disclose, before consumers are asked to reveal billing
information or to consent to any purchase in connection with any claim that a
good or service is “free,” has a minimal cost, or is being offered on a trial basis or
at an introductory or limited-time reduced cost, the following material terms and
conditions of any offer:
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The amount (or range of costs) the consumer will be charged or billed,
including shipping, handling, and processing, and, if applicable, the
frequency of such charges unless the consumer timely takes steps to
prevent or stop them;

3.

The deadline (by date or frequency) by which the consumer must act in
order to stop the recurring charges;

4.

The name of the seller or provider o f the good or service;

5.

A description of the good or service; and

6.

The mechanism to stop any recurring charges.

In addition, for any transaction involving a sale o f a good or service to a consumer
through a Negative Option Feature, within ten (10) days after the date of the sale, Defendants
must send the consumer written confirmation of the transaction, either by email or first class
mail, according to the consumer’s preference, which is identified as a written confirmation in the
email subject line or on the outside of the envelope. Such written confirmation shall include
Clear and Conspicuous disclosure of all the information required by this Subsection XI.B(l)-(6)
above, and shall specify the procedures by which consumers can cancel or obtain a refund.
XII.
EXPRESS INFORMED CONSENT
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined from using billing information to obtain payment from a
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2.

Understands that the transaction includes a Negative Option Feature; and

3.

Understands the specific affirmative steps the consumer must take to
prevent further charges.

Defendants shall maintain for three (3) years from the date of each transaction an unedited voice
recording of the entire transaction, including the prescribed statements set out in the Section of
this Order entitled Required Disclosures. Each recording must be retrievable by date and by the
consumer’s name, telephone number, or billing information and must be provided upon request
and without charge to the consumer, the consumer’s bank, or any law enforcement entity.
XIII.
PROHIBITIONS CONCERNING REFUNDS AND CANCELLATIONS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined from:
A.

Misrepresenting, expressly or by implication, any material term of any refund,
return, or cancellation policy or practice;

B.

Failing to honor a refund, return, or cancellation request that complies with any
policy to make refunds or allow returns or cancellations; and

C.

Failing to provide a simple mechanism for a consumer to immediately stop any
recurring charge for such good or service, at least one of which is as simple and
easy to use as the mechanism the consumer used to initiate the charges.
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actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined, in connection with any person who purchases any good
or service subsequent to the date of this Order, and who uses a debit card or other means of
electronic fund transfer, from:
A.

Failing to obtain written authorization for Preauthorized Electronic Fund
Transfers from a consumer’s account before initiating any Preauthorized
Electronic Fund Transfer, as required by Section 907(a) of the Electronic Fund
Transfer Act, 15 U.S.C. § 1693e(a), and Section 1005.10(b) of Regulation E, 12
C.F.R. § 1005.10(b), as more fully set out in Section 1005.10 of the Consumer
Financial Protection Bureau’s Official Staff Commentary to Regulation E, 12
C.F.R. § 1005, Supp. I; and

B.

Failing to maintain procedures reasonably adapted to avoid an unintentional
failure to obtain written authorization for a Preauthorized Electronic Fund
Transfer, as required in Section 1005.10 of the Consumer Financial Protection
Bureau’s Official Staff Commentary to Regulation E, 12 C.F.R. § 1005, Supp. I.
XVI.
MONETARY JUDGMENT AND PARTIAL SUSPENSION

IT IS FURTHER ORDERED that:
A.

Judgment is hereby entered in favor of Plaintiffs and against Defendants, jointly
and severally, in the amount of $6,574,957, as equitable monetary relief;

B.

Defendants are ordered to pay to the Commission $ 131,000, such payment to be
made to the Commission no later than April 30, 2017 by electronic funds transfer

23

Case l:1 7 -cv-0 0 0 6 7 -N T

3.

D ocum ent 25

Filed 03/10/17

Page 25 of 37

PagelD #: 316

The email from Defendants’ attorney to Plaintiffs dated September 16,
2016, explaining Jeffrey R. Powlowsky’s other financial interests; and

4.

Additional financial documents supplied by Defendants’ attorney to
Plaintiffs on September 19, 21, 23, 27, and 28, 2016;

F.

The suspension o f the judgment will be lifted as to any Defendant if, upon motion
by either of Plaintiffs, the Court finds that such Defendant failed to disclose any
material asset or income, materially misstated the value of any asset, or made any
other material misstatement or omission in the financial representations identified
in Subsection E, above;

G.

If the suspension of the judgment is lifted, this judgment becomes immediately
due as to the defendant or defendants causing the suspension to be lifted in the
amount specified in Subsection A, above (which the parties stipulate only for
purposes of this Section represents the consumer injury alleged in the Complaint),
less any payment previously made pursuant to this Section, plus interest computed
from the date of entry of this Order;

H.

All money paid to the Commission pursuant to this Order may be deposited
into a fund administered by the Commission or its designee to be used for
equitable relief, including consumer redress and any attendant expenses for the
administration of any redress fund, or for other equitable relief such as consumer
informational remedies. If a representative of the Commission decides that such
equitable remedies are wholly or partially impracticable, the remaining money
shall be divided with the State of Maine. Any money not used by the FTC for
equitable relief or transferred to the State of Maine is to be deposited to the U.S.
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XVII.
COOPERATION WITH FTC AND MAINE
IT IS FURTHER ORDERED that Defendants must fully cooperate with representatives
o f the Commission, the Maine AG, and any of their representatives in this case and in any
investigation related to or associated with the transactions or the occurrences that are the subject
of the Complaint. Defendants must provide truthful and complete information, evidence, and
testimony. Individual Defendant must appear and Corporate Defendant must cause its partners,
officers, employees, representatives, or agents to appear for interviews, discovery, hearings,
trials, and any other proceedings that a representative of the Commission or the Maine AG may
reasonably request upon five (5) days’ written notice, or other reasonable notice, at such places
and times as a Commission or Maine AG representative may designate, without the service of a
subpoena.
XVIII.
CUSTOMER INFORMATION
IT IS FURTHER ORDERED that Defendants’ officers, agents, and employees, and all
other persons in active concert or participation with any of them, who receive actual notice of
this Order, are permanently restrained and enjoined from directly or indirectly:
A.

Failing to provide sufficient customer information in their possession, custody, or
control to Plaintiffs to enable the Commission to efficiently administer consumer
redress. If a representative of the Commission requests in writing any
information related to redress, Defendants must provide it, in the form prescribed
by the Commission, within fourteen (14) days;

B.

Disclosing, using, or benefitting from customer information, including the name,
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majority owner or controls directly or indirectly, and Corporate Defendant, must
deliver a copy of this Order to:
1.

All principals, officers, directors, LLP and LLC partners, managers, and
members;

2.

All employees, agents, and representatives who participate in the
manufacturing, labeling, advertising, marketing, distribution, or sale of
any Covered Product or service; and

3.

Any business entity resulting from any change in structure as set forth in
the Section titled Compliance Reporting.
Delivery must occur within 7 days of entry of this Order for
current personnel. For all others, delivery must occur before they assume
their responsibilities.

C.

From each individual or entity to which a Defendant delivered a copy of this
Order, that Defendant must obtain, within 30 days, a signed and dated
acknowledgment of receipt of this Order.
XX.
COMPLIANCE REPORTING

IT IS FURTHER ORDERED that Defendants make timely submissions to the
Commission and to the Maine AG:
A.

60 days after entry o f this Order, each Defendant must submit a
compliance report, sworn under penalty of perjury:
1.

Each Defendant must: (a) identify the primary physical, postal, and email
address and telephone number as designated points of contact, which
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contact; (b) the structure of Corporate Defendant or any entity that
Defendants have any ownership interest in or control directly or indirectly
that may affect compliance obligations arising under this Order,
including: creation, merger, sale, or dissolution of the entity or any
subsidiary, parent, or affiliate that engages in any acts or practices subject
to this Order.
2.

Additionally, Individual Defendant must report any change in:
(a) names, including aliases or fictitious names, or residence addresses; or
(b) titles or roles in any business activity, including any business for which
such Defendant performs services whether as employees or otherwise
and any entity in which such Defendant has any ownership interest, and
identify the name, physical address, and any Internet address of the
business or entity.

C.

For a period of 10 years, each Defendant must submit to the Commission
and the Maine AG notice of the filing of any bankruptcy petition, insolvency
proceeding, or similar proceeding by or against such Defendant within 14 days
of its filing.

D.

Any submission to the Commission or the Maine AG required by this Order
to be sworn under penalty of perjury must be true and accurate and comply with
28 U.S.C. § 1746, such as by concluding: “I declare under penalty of perjury
under the laws o f the United States of America that the foregoing is true and
correct. Executed on: ________ ” and supplying the date, signatory’s full name,
title (if applicable), and signature.
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Personnel records showing, for each person providing services, whether as an
employee or otherwise, that person’s: name; address; telephone numbers; job title
or position; dates of service; and (if applicable) the reason for termination;

C.

Complaints and full or partial refund requests, whether received directly or
indirectly, such as through a third party, and any response;

D.

All records necessary to demonstrate full compliance with each provision of this
Order, including all submissions to the Commission and the Maine AG; and

E.

A copy of each unique advertisement or other marketing material.
XXII.
COMPLIANCE MONITORING

IT IS FURTHER ORDERED that, for the purpose of monitoring Defendants’
compliance with this Order, including the financial representations upon which part of the
judgment was suspended, and any failure to transfer any assets as required by this Order:
A.

Within 14 days of receipt of a written request from a representative of
the Commission or the Maine AG, each Defendant must: submit additional
compliance reports or other requested information, which must be sworn under
penalty of perjury; appear for depositions; and produce documents for inspection
and copying. Plaintiffs are also authorized to obtain discovery, without further
leave of court, using any of the procedures prescribed by Federal Rules of Civil
Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45, and 69.

B.

For matters concerning this Order, the Plaintiffs are authorized to
communicate directly with each Defendant. Defendants must permit Plaintiffs’
representatives to interview any employee or other person affiliated with any
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XXIII.
RETENTION OF JURISDICTION
IT IS FURTHER ORDERED that this Court shall retain jurisdiction of this matter for
purposes of construction, modification, and enforcement of this Order.
IT IS SO ORDERED this 10th day of March, 2017.

/s/ Nancy Torresen___________________
United States Chief District Judge

IT IS SO STIPULATED this 15 day of February, 2017.
DAVID C. SHONKA
Acting General Counsel
/s/ James A. Pruntv
James A. Prunty
David P. Frankel
Federal Trade Commission
600 Pennsylvania Avenue, NW
Room CC-10562
Washington, D.C. 20580
Telephone: 202-326-2438, 2812
Facsimile: 202-326-3259
Email: jprunty@ftc.gov
dfrankel@ftc.gov
Attorneys for Plaintiff
FEDERAL TRADE COMMISSION
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ATTORNEYS FOR DEFENDANTS XXL
IMPRESSIONS LLC and JEFFREY R.
POWLOWSKY
/s/ William C. Halls
William C. Halls, Esq.
Pro Hac Vice forthcoming
Halls Law Office
4180 Woodland View Drive
Kamas, Utah 84036
/si Alfred C. Frawlev
Alfred C. Frawley
Senior Counsel
Eaton Peabody
One Portland Square, 7th Floor
P.O. Box 15235
Portland, Maine 04112-5235
Telephone: 207-430-8805
Facsimile: 207-274-5286
Email: ffrawley@eatonpeabody.com
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE OF MAINE,
Plaintiffs,
v.

XXL IMPRESSIONS LLC, a limited liability
company, also d/b/a BETTER HEALTH
NUTRITIONALS,
JEFFREY R. POWLOWSKY, individually
and as an owner and officer of XXL
IMPRESSIONS LLC,
J2 RESPONSE L.L.P., a limited liability
partnership, also d/b/a J2 RESPONSE,
JUSTIN BUMANN, individually
and as partner of J2 RESPONSE L.L.P.,
JUSTIN STEINLE, individually and as a
partner o f J2 RESPONSE L.L.P.,
SYNERGIXX, LLC, a limited liability
company, also d/b/a CTF MEDIA,
CHARLIE R. FUSCO, individually
and as an owner and officer of SYNERGIXX,
LLC,
RONALD JAHNER, and
BRAZOS MINSHEW a/k/a SAMUEL BRANT,
Defendants.

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
J
)
)
)
)
)
)
)

Case No. l:17-cv-0006-NT

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANTS J2 RESPONSE L.L.P.
d/b/a J2 RESPONSE, JUSTIN
BUMANN, and JUSTIN STEINLE

Receipt of the above-captioned STIPULATED FINAL JUDGMENT AND ORDER FOR
PERMANENT INJUNCTION OTHER EQUITABLE RELIEF is hereby acknowledged.

¿U.

JustitfBumann
February®?, 2017

Justin Steinle
February a-?, 2017

J2 Response, L.L.P
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE OF MAINE,
Plaintiffs,

)
)
)
) Case No.

)

)
)
)
)
)
XXL IMPRESSIONS LLC, a limited liability
)
company, also d/b/a BETTER HEALTH
)
NUTRITIONALS,
)
JEFFREY R. POWLOWSKY, individually
)
and as an owner and officer of XXL
)
IMPRESSIONS LLC,
)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)
v.

STIPULATED FINAL JUDGMENT
AND ORDER FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF AS TO
DEFENDANTS J2 RESPONSE L.L.P.
d/b/a J2 RESPONSE, JUSTIN
BUMANN, and JUSTIN STEINLE
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FINDINGS
1.

This Court has jurisdiction over this matter.

2.

The Complaint charges that Defendants participated in deceptive acts or practices

in violation o f Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, the
Telemarketing and Consumer Fraud and Abuse Prevention Act (“Telemarketing Act”), 15
U.S.C. §§ 6101-6108, the FTC’s Trade Regulation Rule entitled “Telemarketing Sales Rule”
(“TSR”), 16 C.F.R. Part 310, the Electronic Fund Transfer Act (“EFTA”), 15 U.S.C. §§ 16931693r, and its implementing Regulation E, 12 C.F.R. § 1005.10, and Section 207 of the Maine
UTPA, M e . Re v . Stat. tit. 5, § 207, in connection with the labeling, advertising, marketing,
distribution, and sale of products purported to provide pain relief and to prevent or mitigate
cognitive decline.
3.

Defendants neither admit nor deny any of the allegations in the Complaint, except

as specifically stated in this Order. Defendants admit the facts necessary to establish jurisdiction
only for purposes of this action.
4.

Defendants waive any claim that they may have under the Equal Access to Justice

Act, 28 U.S.C. § 2412, concerning the prosecution o f this action through the date of this Order,
and agree to bear their own costs and attorney fees.
5.

Defendants and Plaintiffs waive all rights to appeal or otherwise challenge or

contest the validity of this Order.
DEFINITIONS
For the purpose of this Order, the following definitions apply:
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The disclosure must comply with these requirements in each medium
through which it is received, including all electronic devices and face-toface communications;

G.

The disclosure must not be contradicted or mitigated by, or inconsistent
with, anything else in the communication; and

H.

When the representation or sales practice targets a specific audience, such
as children, the elderly, or the terminally ill, “ordinary consumers”
includes reasonable members of that group.

2.

“Close proximity” means that the disclosure is very near the triggering

representation. For example, a disclosure made through a hyperlink, pop-up, interstitial, or other
similar technique is not in close proximity to the triggering representation.
3.

“Corporate Defendant” means J2 Response LLP, also d/b/a J2 Response and its

successors and assigns.
4.

“Covered Product” means any Dietary Supplement, Food, or Drug, including but

not limited to FlexiPrin and CogniPrin.
5.

“Defendants” means Individual Defendants and Corporate Defendant,

individually, collectively, or in any combination.
6.

“Dietary supplement” means:
A.

any product labeled as a dietary supplement or otherwise represented as a
dietary supplement; or

B.

any pill, tablet, capsule, powder, softgel, gelcap, liquid, or other similar
form containing one or more ingredients that are a vitamin, mineral, herb
or other botanical, amino acid, probiotic, or other dietary substance for use
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“Material connection” means any relationship that materially affects the weight

or credibility of any Endorsement and that would not reasonably be expected by consumers.
13.

“Negative Option Feature” means, in an offer or agreement to sell or provide

any good, program, or service, a provision under which the consumer’s silence or failure to make
an affirmative action to reject goods or services, or to cancel the agreement, is interpreted by the
seller or provider as acceptance of the offer.
14.

“Person” means a natural person, an organization, or other legal entity, including

a corporation, partnership, sole proprietorship, limited liability company, association,
cooperative, or any other group or combination acting as an entity.
15.

“Preauthorized Electronic Fund Transfer” as defined by the Electronic Fund

Transfer Act, 15 U.S.C. § 1693a(10), means an electronic fund transfer authorized in advance to
recur at substantially regular intervals.
I.

PROHIBITED REPRESENTATIONS: PAIN RELIEF, CARTILAGE REBUILDING,
COGNITIVE DECLINE, MEMORY IMPROVEMENT, AND DISEASE CLAIMS
IT IS HEREBY ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product, are hereby permanently restrained and enjoined from making, or assisting
others in making, expressly or by implication, including through the use of a product name,
endorsement, depiction, or illustration, any representation that, in humans, such Covered
Product:
A.

Reduces joint pain, inflammation, or stiffness, including in as little as two hours;
7
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II.
PROHIBITED REPRESENTATIONS: OTHER HEALTH-RELATED CLAIMS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product, are permanently restrained and enjoined from making, or assisting others in
making, expressly or by implication, including through the use of a product name, endorsement,
depiction, or illustration, any representation about the health benefits, safety, performance, or
efficacy of any Covered Product, other than a representation covered under the Section of this
Order entitled Prohibited Representations: Pain Relief, Cartilage Rebuilding, Cognitive Decline,
Memory Improvement, and Disease Claims, unless the representation is non-misleading, and, at
the time of making such representation, they possess and rely upon competent and reliable
scientific evidence that is sufficient in quality and quantity based on standards generally accepted
by experts in the relevant disease, condition, or function to which the representation relates,
when considered in light of the entire body of relevant and reliable scientific evidence, to
substantiate that the representation is true.
For purposes of this Section, competent and reliable scientific evidence means tests,
analyses, research, or studies (1) that have been conducted and evaluated in an objective manner
by experts in the relevant disease, condition, or function to which the representation relates;
(2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that
are randomized, double-blind, and placebo controlled human clinical testing of the Covered
Product, or of an Essentially Equivalent Product, when such experts would generally require
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The existence, contents, validity, results, conclusions, or interpretations of any
test, study, or research.
IV.
FDA-APPROVED CLAIMS

IT IS FURTHER ORDERED that nothing in this Order prohibits Defendants,
Defendants’ officers, agents, and employees, or all other persons in active concert or
participation with any of them from:
A.

For any drug, making a representation that is approved in labeling for such drug

under any tentative final or final monograph promulgated by the Food and Drug Administration,
or under any new drug application approved by the Food and Drug Administration; and
B.

For any product, making any representation that is specifically authorized for use

in labeling for such product by regulations promulgated by the Food and Drug Administration
pursuant to the Nutrition Labeling and Education Act of 1990 or permitted under Sections 303304 of the Food and Drug Administration Modernization Act of 1997.
V.
PRESERVATION OF RECORDS RELATING TO COMPETENT AND RELIABLE
HUMAN CLINICAL TESTS OR STUDIES
IT IS FURTHER ORDERED that, with regard to any human clinical test or study
(“test”) upon which Defendants rely to substantiate any claim covered by this Order, Defendants
shall secure and preserve all underlying or supporting data and documents generally accepted by
experts in the field as relevant to an assessment of the test, including:
A.

All protocols and protocol amendments, reports, articles, write-ups, or other
accounts of the results of the test, and drafts of such documents reviewed by the
test sponsor or any other person not employed by the research entity;
11

Case l:1 7 -cv-0 0 0 6 7 -N T

Docum ent 24

Filed 03/10/17

Page 13 of 35

PagelD #: 269

For any test conducted, controlled, or sponsored, in whole or in part, by Defendants,
Defendants must establish and maintain reasonable procedures to protect the confidentiality,
security, and integrity o f any personal information collected from or about participants. These
procedures shall be documented in writing and shall contain administrative, technical, and
physical safeguards appropriate to Corporate Defendants’ size and complexity, the nature and
scope of Defendants’ activities, and the sensitivity o f the personal information collected from or
about the participants.
VI.
PROHIBITED REPRESENTATIONS
RELATED TO ENDORSEMENTS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
good or service, are permanently restrained and enjoined from misrepresenting, in any manner,
expressly or by implication, including through the use of any good or service name,
endorsement, depiction, or illustration, that:
A.

Any person is an expert with respect to the Endorsement message provided by
that person;

B.

Purported consumers who appear in advertising obtained a reported result through
use of those goods or services;

C.

Experts are providing their objective, independent opinions regarding the efficacy
of any good or service; and

D.

Any advertising is objective news or informational programming.
13
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VIII.
DISCLOSURE OF MATERIAL CONNECTIONS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
good or service, are permanently restrained and enjoined from making any representation,
expressly or by implication, including through the use of a good or service name, endorsement,
depiction, or illustration, about any endorser of a good or service unless they disclose, Clearly
and Conspicuously, and in Close Proximity to the representation, a Material Connection, when
one exists, between such endorser and Defendants or any other individual or entity
manufacturing, labeling, advertising, promoting, offering for sale, selling, or distributing such
good or service.
IX.
OTHER PROHIBITED MISREPRESENTATIONS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined from misrepresenting, or assisting others in
misrepresenting, expressly or by implication, any material fact, including, but not limited to:
A.

That consumers are receiving a money-back guarantee, a free trial offer, a risk
free trial offer, a free gift, or a bonus;
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In close proximity to such claim, the total cost to purchase, receive, or use
any good or service that is the subject of the sales offer, including
shipping, handling, and processing;

2.

The amount, timing, and manner o f payment of all fees, charges, or other
amounts that a consumer will be charged or billed, and any additional
financial obligations that may be incurred as a result of accepting the free
product, service, or offer; and

3.

The terms and conditions of any refund, cancellation, exchange, or
purchase policy or policies, including the specific steps and means by
which such requests must be submitted, and the telephone number, email
address, web address, or street address to which such requests must be
directed, including the deadline (by date or frequency) by which the
consumer must act, and, if there is a policy of not making refunds,
cancellations, exchanges, or repurchases, a statement regarding this
policy; and

B.

Failing to Clearly and Conspicuously disclose, or assisting others in failing to
Clearly and Conspicuously disclose, before consumers are asked to reveal billing
information or consent to any purchase that includes a Negative Option Feature:
1.

That the consumer will be charged for the good or service, or that the
charges will increase after the trial period ends, and if applicable, that the
charges will be on a recurring basis, unless the consumer timely takes
steps to prevent or stop such charges;
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consumer, unless, prior to using such billing information to obtain payment, Defendants obtain
the express informed consent of the consumer.
A.

For all written offers with a Negative Option Feature (including over the Internet
or other web-based applications or services), a consumer’s express informed
consent shall be obtained, prior to Defendants’ obtaining any billing information
from consumers, through a check box, signature, or other substantially similar
method, that consumers must affirmatively select or sign to accept the Negative
Option Feature. Immediately adjacent to such check box, signature, or
substantially similar method, Defendants shall disclose all costs associated with
the Negative Option Feature, including shipping, handling, and processing, that
the consumer is agreeing to pay such costs, the length of any trial period, and the
date by which consumers must cancel to avoid being charged. This disclosure
shall contain no additional information and shall be Clear and Conspicuous in
relation to any other information provided on the page relating to costs, risks, or
obligations associated with any Negative Option Feature, including any terms
referring to “free,” “trial,” and “processing fee.”

B.

For all oral offers including a Negative Option Feature, Defendants shall, in
addition to disclosing the information identified in the Section of this Order
entitled Required Disclosures and prior to obtaining any billing information from
a consumer, obtain affirmative and unambiguous oral confirmation that the
consumer:
1.

Consents to authorizing payment for any goods or services, including
shipping, handling, and processing;
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For consumers who entered into the agreement to purchase a good or
service including a Negative Option Feature over the Internet or through
other web-based applications or services, Defendants must provide a
mechanism for consumers to stop the recurring charge over the Internet or
through such other web-based application or service.

2.

For consumers who entered into the agreement to purchase a good or
service including a Negative Option Feature through an oral offer and
acceptance, Defendants must maintain a telephone number through which
the consumer can easily cancel the good or service, seek a refund for past
charges, and immediately stop all further charges. Defendants must
answer all calls to this telephone number during normal business hours.
XIII.

PROHIBITION ON VIOLATING THE RESTORE ONLINE SHOPPERS’
CONFIDENCE ACT
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined from violating the Restore Online Shoppers’ Confidence
Act, 15 U.S.C. §§ 8401-8405, a copy of which is attached hereto as EXHIBIT A.
XIV.
COM PLIANCE W ITH THE ELECTRONIC FUND TRANSFER ACT
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
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payment to the Commission. Such payment must be made within 7 days of entry
of this Order by electronic funds transfer in accordance with instructions
previously provided by a representative of the Commission.
C.

Upon satisfaction of the obligations described in Subsection B, above, the
remainder o f the judgment as to the Defendants shall be suspended subject to
Subsections E and F below;

D.

In the event of default on any obligation to make payments under this Order,
including, but not limited to, failure to pay $425,000 to the FTC pursuant to
Section B, above, interest shall accrue as computed pursuant to 28 U.S.C. §
1961(a) from the date of default to the date o f payments. In the event such default
continues for ten (10) calendar days beyond the date any payments are due, the
entire judgment amount of $6,574,957 shall immediately become due and
payable. Defendants shall be jointly and severally liable with all remaining
defendants named in the Complaint filed in this action for all payments required
by this Subsection and any interest on such payments;

E.

Plaintiffs’ agreement to the suspension of part of the judgment is expressly
premised upon the truthfulness, accuracy, and completeness of Defendants’ sworn
financial statements, and related documents (collectively, “financial
representations”) submitted to Plaintiffs, namely, the following:
1.

Individual and corporate financial disclosures, together with all
attachments, submitted to Plaintiffs on July 6, 2016;

2.

Emails from counsel dated July 27, 2016 and August 3, 2016 clarifying
financial questions;
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Treasury as disgorgement. Defendants have no right to challenge any actions the
Commission or its representatives may take pursuant to this Subsection;
I.

All money paid to the State of Maine pursuant to this Order shall be
deposited into the Attorney General’s other special revenue account and used for
consumer education, consumer protection, antitrust enforcement, or for any lawful
purpose at the sole discretion of the Attorney General;

J.

Defendants relinquish dominion and all legal and equitable right, title, and interest
in all assets transferred pursuant to this Order and may not seek the return of
any assets;

K.

The facts alleged in the Complaint will be taken as true, without further proof, in
any subsequent civil litigation by or on behalf of either of Plaintiffs, including in a
proceeding to enforce their rights to any payment or monetary judgment pursuant
to this Order, such as a nondischargeability complaint in any bankruptcy
case.

L.

The facts alleged in the Complaint establish all elements necessary to sustain an
action by either of Plaintiffs pursuant to Section 523(a)(2)(A) of the Bankruptcy
Code, 11 U.S.C. § 523(a)(2)(A), and this Order will have collateral estoppel
effect for such purposes; and

M.

Defendants acknowledge that their Taxpayer Identification Numbers (Social
Security Numbers or Employer Identification Numbers), which Defendants must
submit to Plaintiffs, may be used for collecting and reporting on any delinquent
amount arising out of this Order, in accordance with 31 U.S.C. § 7701.
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address, telephone number, email address, Social Security number, other
identifying information, or any data that enables access to a customer’s account
(including a credit card, bank account, or other financial account), that any
Defendant obtained prior to entry of this Order in connection with the
labeling, advertising, marketing, distribution, or sale of any formulation of
FlexiPrin or CogniPrin; and
C.

Failing to destroy such customer information in all forms in their possession,
custody, or control within thirty (30) days after receipt of written direction to do
so from representatives of both the Commission and the Maine Attorney
General’s Office.

Provided, however, that customer information need not be destroyed, and may be
disclosed, to the extent requested by a government agency or required by law, regulation, or
court order.
XVIII.
ORDER ACKNOWLEDGMENTS
IT IS FURTHER ORDERED that Defendants obtain acknowledgments of receipt of
this Order:
A.

Each Defendant, within 7 days of entry of this Order, must submit to
the Commission and the State of Maine an acknowledgment of receipt of this
Order sworn under penalty of perjury.

B.

For 10 years after entry of this Order, Individual Defendants for
any business involved in the sale or marketing o f any Covered Product that
such Defendants, individually or collectively with Corporate Defendant, is the
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Plaintiffs’ representatives may use to communicate with Defendant;
(b) identify all of that Defendant’s businesses by all of their names,
telephone numbers, and physical, postal, email, and Internet addresses;
(c) describe the activities of each business, including the goods and
services offered, the means of advertising, marketing, and sales, and the
involvement of any other Defendants (which Individual Defendants must
describe if they know or should know due to their own involvement);
(d) describe in detail whether and how that Defendant is in compliance
with each Section of this Order; and (e) provide a copy of each
Order Acknowledgment obtained pursuant to this Order, unless
previously submitted to Plaintiffs.
2.

Additionally, Individual Defendants must: (a) identify all telephone
numbers and all physical, postal, email, and Internet addresses, including
all residences; (b) identify all business activities, including any business
for which such Defendants perform services whether as employees or
otherwise and any entity in which such Defendants have any ownership
interest; and (c) describe in detail such Defendants’ involvement in each
such business, including title, role, responsibilities, participation,
authority, control, and any ownership.

B.

For 10 years after entry of this Order, each Defendant must submit
a compliance notice, sworn under penalty of perjury, within 14 days of
any change in the following:
1.

Each Defendant must report any change in: (a) any designated point of
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Unless otherwise directed by a Commission representative in writing, all
submissions to the Commission pursuant to this Order must be emailed to
DEBrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to:
Associate Director for Enforcement, Bureau of Consumer Protection, Federal
Trade Commission, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580.
The subject line must begin: FTC v. XXL Impressions et al., and the number
X____________ .

F.

Unless otherwise directed by a Maine AG representative in writing, all
submissions to the Maine AG pursuant to this Order must be sent by
overnight courier (not the U.S. Postal Service) to: Office of the Attorney General
of Maine, Consumer Protection Division, 111 Sewall Street, 6th Floor, Augusta,
ME 04330. The subject line must begin: Order in re State o f Maine v.
XXL Impressions et al., and must identify the Court and docket number of
this Order as ordered by the Court.

XX.
RECORDKEEPING
IT IS FURTHER ORDERED that in connection with the sale o f any Covered Product,
Defendants must create certain records for 10 years after entry of the Order, and retain each such
record for 5 years. Specifically, Corporate Defendant and Individual Defendants for any
business that such Defendants, individually or collectively with any other Defendants, is a
majority owner or controls directly or indirectly, must create and retain the following records:
A.

Accounting records showing the revenues from all goods or services sold, all
costs incurred in generating those revenues, and the resulting net profit or loss;
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Defendant who has agreed to such an interview. The person interviewed may
have counsel present.
C.

Plaintiffs may use all other lawful means, including posing, through their
representatives, as consumers, suppliers, or other individuals or entities, to
Defendants or any individual or entity affiliated with Defendants, without the
necessity of identification or prior notice. Nothing in this Order limits the
Commission’s lawful use of compulsory process, pursuant to Sections 9 and 20 of
the FTC Act, 15 U.S.C. §§ 49, 57b-l. Nothing in this Order limits the
Maine AG’s lawful use of compulsory process, pursuant to section 211 of the
Maine UTPA, M e . Rev . Stat . tit. 5, §211. Defendants hereby consent to the
disclosure by the Maine AG to any law enforcement agency and any
representative of the State of Maine of any material or information produced by
Defendants pursuant to section 211 of the Maine UTPA, whether produced before
or after the date of this Order.

D.

Upon written request from a representative of the Commission or the State of
Maine, any consumer reporting agency must furnish consumer reports concerning
individual Defendants, pursuant to Section 604(1) of the Fair Credit Reporting
Act, 15 U.S.C. § 168lb(a)(l).
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IT IS SO STIPULATED this 13 day of February, 2017.

/s/ Justin Bumann
Defendant Justin Bumann

IT IS SO STIPULATED this 13 day o f February, 2017.

/s/ Justin Steinle
Defendant Justin Steinle

IT IS SO STIPULATED this 13 day of February, 2017.
/s/ Justin Steinle
B y _____________________________
On behalf of Defendant J2 Response, L.L.P
ATTORNEY FOR DEFENDANTS J2
RESPONSE, L.L.P., JUSTIN BUMANN,
and JUSTIN STEINLE
/s/ Marc Roth
Marc Roth, Esq.
Manatt, Phelps & Phillips, LLP
Pro Hac Vice forthcoming
7 Times Square
New York, NY 10036
Telephone: (212) 790-4542
Email: mroth@inanatt.com
John D. Clifford, IV
Clifford & Golden, P.A.
5 Maple Street, P.O. Box 368
Lisbon Falls, ME 04552
Telephone: (207) 353-9366
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IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE OF MAINE,
Plaintiffs,
V.

XXL IMPRESSIONS LLC, a limited liability
company, also d/b/a BETTER HEALTH
NUTRITIONALS,
JEFFREY R. POWLOWSKY, individually
and as an owner and officer of XXL
IMPRESSIONS LLC,

)
)
)
)
)
)
)
)
)
)
)

)
)
)

)

)
)
J2 RESPONSE L.L.P., a limited liability
)
partnership, also d/b/a J2 RESPONSE,
)
)
JUSTIN BUMANN, individually
)
and as a partner of J2 RESPONSE L.L.P.,
)
)
JUSTIN STEINLE, individually and as a
)
partner of J2 RESPONSE L.L.P.,
)
)
SYNERGIXX, LLC, a limited liability
)
company, also d/b/a CTF MEDIA,
)
)
CHARLIE R. FUSCO, individually
)
and as an owner and officer of SYNERGIXX,
)
LLC,
)
)
RONALD JAHNER, and
)
)
BRAZOS MINSHEW a/k/a SAMUEL BRANT, )
)
Defendants.
)
)

Case No.

COMPLAINT FOR PERMANENT
INJUNCTION AND OTHER
EQUITABLE RELIEF
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JURISDICTION AND VENUE
3.

This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1337(a),

and 1345, and 15 U.S.C. §§ 45(a), 53(b), 1607(c), 6102(c), and 6105(b).
4.

This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 6103(a) and

supplemental jurisdiction over the claims of the State of Maine pursuant to 28 U.S.C. § 1367.
5.

Venue is proper in this district under 28 U.S.C. § 1391(b), (c), and (d), and 15

U.S.C. §§ 53(b) and 6103(e).
PLAINTIFFS
6.

The FTC is an independent agency of the United States Government created by

statute. 15 U.S.C. §§ 41-58. The FTC enforces Section 5(a) of the FTC Act, 15 U.S.C. § 45(a),
which prohibits unfair or deceptive acts or practices in or affecting commerce. The FTC also
enforces Section 12 of the FTC Act, 15 U.S.C. § 52, which prohibits false advertisements for
food, drugs, devices, services, or cosmetics in or affecting commerce; the TSR, which prohibits
deceptive and abusive telemarketing acts or practices; and the EFTA, which regulates the rights,
liabilities, and responsibilities of participants in electronic fund transfer systems.
7.

The FTC is authorized to initiate federal district court proceedings, by its own

attorneys, to enjoin violations of the FTC Act, the TSR, and the EFTA, and to secure such
equitable relief as may be appropriate in each case, including rescission or reformation of
contracts, restitution, the refund of monies paid, and the disgorgement of ill-gotten monies. FTC
Act, 15 U.S.C. § 53(b), TSR, 15 U.S.C. §§ 6102(c), 6105(b), and EFTA, 15 U.S.C. § 1693o(c).
8.

Plaintiff State of Maine is one of fifty sovereign states of the United States. Janet

T. Mills is the duly elected and qualified Attorney General acting for Plaintiff State of Maine and
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Defendant Jeffrey R. Powlowsky (“Powlowsky”) is the sole manager and member

of XXL Impressions and is its sole owner. At all times material to this Complaint, he has
identified his principal place of business to consumers, businesses, and the general public as 165
Pleasant Avenue, South Portland, Maine. At all times material to this Complaint, acting alone or
in concert with others, Powlowsky has formulated, directed, controlled, had the authority to
control, or participated in the acts and practices of XXL Impressions, including the acts and
practices set forth in this Complaint. In connection with the matters alleged herein, he transacts
or has transacted business in this District and throughout the United States and Canada.
13.

Defendant J2 Response L.L.P., also doing business as J2 Response (“J2

Response”), is a North Dakota limited liability partnership. At all times material to this
Complaint, J2 Response’s principal place o f business has been 547 S. 7 Street, #305, Bismarck,
ND 58504, where it has marketed a variety of products, including FlexiPrin and CogniPrin. At
all times material to this Complaint, acting alone or in concert with others, J2 Response has
advertised, marketed, distributed, sold, or offered for sale these products in this District and
throughout the United States and Canada.
14.

Defendant Justin Bumann (“Bumann”) is a 50 percent owner of J2 Response. At

all times material to this Complaint, Bumann’s principal place of business has been 547 S. 7
Street, #305, Bismarck, ND 58504. Acting alone, or in concert with others, Bumann has
formulated, directed, controlled, had the authority to control, or participated in the acts and
practices of J2 Response, including the acts and practices set forth in this Complaint. In
connection with the matters alleged herein, he transacts or has transacted business in this District
and throughout the United States and Canada.
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and Canada. Hereafter Defendants Fusco and Synergixx shall be referred to collectively as “the
Fusco Defendants.”
18.

Defendant Ronald Jahner (“Jahner”) lives in Buffalo Grove, Illinois, where he

works as a board-certified naturopathic physician. He owns and manages naturopathic clinics in
Algonquin and Parkridge, Illinois. Jahner has acted as a paid expert endorser for CogniPrin and
FlexiPrin, appearing as Dr. Ronald Jahner in radio and print advertising throughout the United
States and in Canada. He also has promoted CogniPrin and FlexiPrin through website
advertising, is credited as the author of books promoting CogniPrin and FlexiPrin, and has
trained XXL Impressions’ third-party sales representatives how to promote the products. At all
times material to this Complaint, acting alone or in concert with others, Jahner has transacted
business in this District and throughout the United States and Canada.
19.

Defendant Brazos Minshew (“Minshew”) lives in Scottsdale, Arizona. He has

acted as an expert endorser for CogniPrin, appearing under the pseudonym “Samuel Brant,” a
purported “brain scientist,” in radio and print advertising nationwide and in Canada. He also has
trained XXL Impressions’ inbound call-room representatives how to promote CogniPrin. At all
times material to this Complaint, acting alone or in concert with others, Minshew has transacted
business in this District and throughout the United States and Canada.
COMMERCE
20.

At all times material to this Complaint, all of the Defendants have maintained a

substantial course of trade in or affecting commerce, as “commerce” is defined in Section 4 of
the FTC Act, 15 U.S.C. § 44, and as “trade and commerce” are defined in Section 206(3) of the
Maine UTPA, M e . Re v . Stat . tit. 5, § 206(3).
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be talking about pain today.” Defendant Fusco then introduces Defendant Jahner as a
naturopathic physician with expertise in pain management. Exh. A -l (FlexiPrin radio audio file)
at 00:25-00:39; 01:18-01:33; Exh. A-2 (FlexiPrin radio transcript excerpt) at 3:14-19; and 4:1015. Defendant Fusco does not disclose in the advertisement that the toll-free number she gives
consumers to claim their “free supply” is that o f a call center owned by the Fusco Defendants.
Furthermore, the Powlowsky Defendants pay Defendants Jahner and Synergixx a percentage of
revenues generated from FlexiPrin sales. However, Defendants Fusco and Jahner do not disclose
these royalty payments, nor do they disclose that the show is actually an advertisement paid for
by the Powlowsky Defendants, thereby implying that Defendants Jahner and Fusco are stating
independent, objective, and, in the case of Jahner, expert opinions about FlexiPrin. Exh. A-l
(FlexiPrin radio audio file); Exh. A-2 (FlexiPrin radio transcript excerpt).
24.

In the radio ad, Defendant Jahner states “[FlexiPrin] targets the tissue and it’s an

amazing anti-inflammatory. But the best part is [that] it works fast. Within two hours, people
are getting relief.” Exh. A -l (FlexiPrin radio audio file) at 06:28-06:36; Exh. A-2 (FlexiPrin
radio transcript excerpt) at 7:11-15. Defendant Jahner goes on to state: “[M]ost people actually
experience relief in the first two hours to two days. Those clinical studies I mentioned showed
that 80 percent of the participants were able to reduce or eliminate their pain medications. . . .
And, in fact, in that same four week period, one month, 100 percent of the participants were able
to perform their daily tasks better, reported less stiffness in the morning.” Exh. A -l (FlexiPrin
radio audio file) at 07:07-07:31; Exh. A-2 (FlexiPrin radio transcript excerpt) at 8:8-18.
25.

During the radio program, Defendant Fusco states that “the manufacturers are

guaranteeing people that they’re going to get out of pain in as little as two hours, because these
five ingredients are so powerful.” Exh. A-l (FlexiPrin radio audio file) at 05:12-05:19; Exh. A-2
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A FlexiPrin print ad created by Defendants Synergixx, Fusco, J2 Response,

Bumann, and Steinle, and reviewed and approved by Defendants XXL Impressions and
Powlowsky, begins with the headline “Thousands Combat Back Pain in 2 Hours Without
Side Effects . . The print ad goes on to claim that FlexiPrin’s “Natural ‘fire extinguishing’
nutrients quelch inflammation that causes lower, middle and upper back pain as well as
improves stiffness in joints and revives f l e x i b i l i t y Defendant Jahner then claims:
By reducing inflammation you reduce pain and you encourage healing. This allows the
other proprietary ingredients in Flexiprin™ to start repairing and rebuilding the
cartilage within your joints —which gives you amazingfreedom and allows you to start
living your life a g a in - PAIN FREE!
Exh. B (FlexiPrin print ad) (emphasis in original).
30.

In that print ad, the Powlowky Defendants and the Fusco Defendants claim that

“FlexiPrin™ s ingredients have been proven effective in multiple clinical studies” and “Clinical
Studies Prove 2 Hour Pain Relief.” The Powlowsky Defendants and the Fusco Defendants
further claim:
And the clinical results are nothing short of impressive. Immediately FlexiPrin™
can improve joint comfort and flexibility in as little as 2 hours . . . Long term, in
about 4 weeks, 80% of users reported using less medication or stopped taking
them all together [s/c].
Exh. B (FlexiPrin print ad) (emphasis in original).
31.

Defendant Jahner also appears on the FlexiPrin website created by or at the

direction of Defendants J2 Response, Bumann, and Steinle, and approved by Defendants XXL
Impressions and Powlowsky, www.flexiprin.com. Exh. C (FlexiPrin website). From at least
January 1, 2012 through January 7, 2015, that website prominently displayed a column with
Defendant Jahner’s image and a description of his credentials, accompanied by the claim:
Dr. Ronald Jahner recommends FlexiPrin™ within his practice and the results
have been a miracle[,] as his patients stated . . .
11
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inflammation while they rebuild joint cartilage.” Exh. C (FlexiPrin website), at 2. The website
claims that “FlexiPrin™ also provides clinically proven nutrients to help rebuild . . . cartilage . . .
that has been . .. damaged.” Exh. C (FlexiPrin website), at 2.
34.

A print ad created by Defendants Synergixx, Fusco, J2 Response, Bumann, and

Steinle and reviewed and approved by Defendants XXL Impressions and Powlowsky features
testimonials from product endorsers who claim that FlexiPrin provides immediate pain relief
more effectively than prescription drugs. “R. Kelly” claims that “[ajfter one dose of FlexiPrin™
I knew that I could be pain free again.” In that same print ad, “Scott P” claims, “I had major
back surgery. I was told it would be months before I could move around easily and even longer
before i [s/c] could ween [sic] off the pain medications. FlexiPrin™ had me moving around in
under 30-days.” Exh. B (FlexiPrin print ad). The Powlowsky Defendants and the Fusco
Defendants have no basis for determining the existence or truthfulness of these endorsers, and
they do not know how these endorsers, if they exist, may be identified or contacted.
35.

The Powlowsky Defendants paid Defendant Jahner to train their call

center representatives to repeat advertising claims to customers that the product works as
advertised and has been clinically proven to work. Inbound sales scripts created by
Defendants Synergixx, Fusco, J2 Response, Bumann, and Steinle, and reviewed and
approved by Defendants XXL Impressions and Powlowsky, claim that FlexiPrin is
clinically proven to reduce inflammation and rebuild cartilage.
COGNIPRIN ADVERTISING
36.

One bottle of CogniPrin sells for approximately $32 to $65 and contains 60

capsules. It is usually sold as part of a minimum order of three bottles for $99.90. The
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percent more than you do today, or . . . getting back the memory you had up to 12
years ago.
Exh. D -l (CogniPrin/Minshew radio audio file) at 15:00-15:14; Exh. D-2 (CogniPrin/Minshew
radio transcript excerpt) at 7:11-16. Defendant Fusco states, “Again, the reports out of Stanford
University have shown that these brain-specific nutrients can help restore up to 12 years of
memory loss . . . ” Exh. D-l (CogniPrin/Minshew radio audio file) at 07:22-07:29; Exh. D-2
(CogniPrin/Minshew radio transcript excerpt) at 6:9-12.
40.

In this radio ad, Defendant Minshew also claims that “over 64 clinical studies on

the ingredients in CogniPrin prove that we can get back to having a clear, sharp, focused mind
with no brain fog, no forgetfulness.” Exh. D-l (CogniPrin/Minshew radio audio file) at 6:356:46; Exh. D-2 (CogniPrin/Minshew radio transcript excerpt) at 5:21-24. Defendant Minshew
also claims:
CogniPrin is guaranteed to reduce that mental decline . . . . CogniPrin is backed
by research that proves it works. The support includes more than 64 worldwide
clinical studies and more than 2,800 research papers documenting the
effectiveness and safety of this brain-boosting memory-protecting nutrient.
Exh. D -l (CogniPrin/Minshew radio audio file) at 24:56-25:19; Exh. D-2 (CogniPrin/Minshew
radio transcript excerpt) at 10:14-20. Similarly, Defendant Fusco claims, “The research here is
clear. Sixty-four clinical trials and over 2,800 research papers prove that the ingredients in
CogniPrin can give you back the sharp mind you once had.” Exh. D -l (CogniPrin/Minshew
radio audio file) at 7:03-7:15; Exh. D-2 (CogniPrin/Minshew radio transcript excerpt) at 6:4-7.
41.

In the same radio ad, Defendant Minshew claims:

Now, take [CogniPrin] for three weeks and then ask your wife or husband or children or
the people around you, ask them, am I —does it look to you like my processing speed is
speeding up here? Because that should be observable as well as something we
experience.
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*

[CogniPrin] sharpens focus, clears away brain fog and erases 12 years of lost
Memory power.
*

*

*

The ingredients in CogniPrin have been thoroughly researched and are proven
to improve mental function in almost everyone who takes it.
Exh. E-l (CogniPrin/Jahner radio audio file) at 00:42-00:55, 05:09-05:14, 04:42-04:50; Exh. E-2
(CogniPrin/Jahner radio transcript excerpt) at 3:17-21, 5:12-13, 5:3-6.
44.

In this radio ad Defendant Jahner claims that “In fact, the studies say the

ingredient[s] in CogniPrin can improve your memory by up to 44 percent.” Exh. E-l
(CogniPrin/Jahner radio audio file) at 11:39-l 1:44; Exh. E-2 (CogniPrin/Jahner radio transcript
excerpt) at 6:19-20. Similarly, Defendant Jahner claims:
*

*

*

[Bjased on research done at Stanford University, they tested some of the
key ingredients in CogniPrin and they actually were able to show significant
improvement in all aspects of cognitive function. That includes learning,
memory, recalling numbers, names, faces. And the results were so
dramatic that they actually felt that the average person in the study had
reversed their cognitive decline by 10 to 12 years.
Exh. E-l (CogniPrin/Jahner radio audio file) at 16:32-16:56; Exh. E-2 (CogniPrin/Jahner radio
transcript excerpt) at 8:8-15.
45.

In the same radio ad, Defendant Fusco states:

[T]he makers of CogniPrin are making a guarantee to everyone in my listening
audience today. What they’re saying is try CogniPrin just even for three weeks
and you’re going to improve your memory and reduce mental decline or it’s free,
you won’t pay for it.
Exh. E-l (CogniPrin/Jahner radio audio file) at 12:07-12:20; Exh. E-2 (CogniPrin/Jahner radio
transcript excerpt) at 7:6-10.
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and Powlowsky, Defendant Jahner makes claims about the effectiveness o f CogniPrin. Exh. G
(CogniPrin website). The website features a captioned photo of Defendant Jahner, accompanied
by the following text:
Doctor discovers a brain oxygen boosting miracle
that energizes your mind, mood, and memory

in as iittie as 3 weeks.
It sharpens focus, clears away brain fog and erases 12 years of lost
memory power.

Exh. G (CogniPrin website), at 1. On that same website, the Powlowsky Defendants claim:
Dr. Ronald Jahner has dedicated over 30 years of his life to studying,
practicing, and teaching natural alternatives to medicine . . . He has spent
time researching the brain and it’s [sic] cognitive functions of processing
emotions, thoughts, and memories. I t w a s d u r in g th is tim e D r. J a h n e r
d is c o v e r e d C o g n iP rin ™ .

Exh. G (CogniPrin website), at 3-4 (emphasis in original). Nowhere on the CogniPrin website
do either the Powlowsky Defendants or Defendant Jahner disclose that Defendant Jahner
receives a percentage of revenues generated from FlexiPrin sales. Exh. G (CogniPrin website).
50.

On or about March 16, 2014, Defendant Jahner posted a blog entry entitled,

“Cogniprin for Maximizing Brain Power!” on a third-party website, Good Gut Solution Powered
by Crohns.net (www.crohns.net/blog). Exh. H (Good Gut Solution website). In the blog post,
Defendant Jahner makes several efficacy claims about CogniPrin, including:
Thanks to breakthroughs in the nutraceutical world, we can safely and
easily roll back, yes! We can roll back . . .
1. mental decline up to 12 years,
2. improve our memory by 44%,
4. get rid of brain fog,
5. improve recall, and even,
6. wake up brain cells that have been sleeping!
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1 (FlexiPrin radio audio file) at 07:55-08:12; Exh. A-2 (FlexiPrin radio transcript excerpt), at
9:1-8.
54.

In the case of CogniPrin, the radio and print ads claim that “every new customer

will automatically receive a free 30-day supply,” and that CogniPrin will “improve your memory
and reduce mental decline or it’s free, you won’t pay for it.” Exh. E-l (CogniPrin/Jahner radio
audio file) at 12:53-12:57, 12:18-12:21; Exh. E-2 (CogniPrin/Jahner radio transcript excerpt) at
7:19-20,7:9-10.
55.

Consumers who call to order FlexiPrin and CogniPrin are told that there is an

unconditional, 90 Day MONEY BACK GUARANTEE on their orders. However, in order to
receive these products consumers must pay for a 90-day supply, accept a 90-day continuity plan,
and pay an initial shipping charge of $9.95.
56.

Typically, consumers receive their products between 7 and 10 days after placing

the order. Many consumers believe that the 90-day money-back guarantee starts when they
receive the product, giving them 90 days to try it. The Powlowsky Defendants and the Fusco
Defendants do not disclose, either before or after the initial offer, that the Powlowsky Defendants
compute the 90-day money-back guarantee to begin on the date of the initial sales call, nor do
they disclose that the continuity shipment is sent on or before 90 days after the date of the initial
sales call.
57.

When consumers call customer service toward the end of their 90-day trial

periods to cancel their FlexiPrin and CogniPrin orders and get their money back, they discover
that the time for cancellation has expired because the Powlowsky Defendants use the initial order
date — not the date of receipt — as the beginning of the 90-day trial period. Also, the
Powlowsky Defendants ship continuity orders o f FlexiPrin and CogniPrin on or before 90 days
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day continuity plan and must provide a credit or debit card number to pay an initial shipping
charge o f $9.95 in order to receive their free trial.
61.

Consumers who agree to enroll in the 60-day continuity plan are sent a purported

30-day free supply of CogniPrin. Under this plan, a new shipment of CogniPrin is sent to
consumers 21 days after the initial order, and every 60 days thereafter. Because the initial 30day “free trial” supply takes 7 to 10 days to reach consumers, consumers have less than two
weeks to take advantage of their purported 30-day “free trial.” Consumers who choose to cancel
within 30 days of receiving their initial “free trial” often discover that they are too late. Twentyone days after the initial order, the Powlowsky Defendants charge $99.90 to consumers’ credit or
debit card numbers on file for the first 60-day continuity shipment of CogniPrin, plus an
additional $9.95 for shipping. On many occasions, the Powlowsky Defendants refuse to refund
these charges to consumers.
The Powlowsky Defendants’ and the Fusco Defendants’
Offers on Behalf of Third Parties
62.

Once consumers accept the Powlowsky Defendants’ and the Fusco Defendants’

primary offer (i.e., FlexiPrin or CogniPrin), the Fusco Defendants’ inbound sales representatives
offer consumers a series o f “upsells” in the form of additional goods and services sold by third
parties (“external upsells”). The Powlowsky Defendants and the Fusco Defendants receive
commissions when consumers accept free or low-cost trial offers for these additional goods and
services, which are “read on,” in industry parlance, after the initial product sale is completed.
63.

The Powlowsky Defendants and the Fusco Defendants sell two discount buying

clubs together as a package, Savers Central and Holiday Savers, which cost $17.83 per month
each after a low-cost 14-day trial period. They also sell a supplemental health savings plan,
CARExpress Health Savings Program, which costs $39.99 per month after a free 14-day trial
23
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false advertisement in or affecting commerce for the purpose of inducing, or which is likely to
induce, the purchase of food, drugs, devices, services, or cosmetics. For the purposes of Section
12 of the FTC Act, 15 U.S.C. § 52, FlexiPrin and CogniPrin are “drugs,” as defined in Section
15(c) of the FTC Act, 15 U.S.C. § 55(c). The term “false advertisement” means an
advertisement, other than labeling, which is misleading in a material respect. 15 U.S.C.
§ 55(a)(1).
COUNT I
THE POWLOWSKY DEFENDANTS’ AND THE FUSCO DEFENDANTS’ FALSE OR
UNSUBSTANTIATED CLAIMS ABOUT FLEXIPRIN
68.

Through the means described in Paragraphs 24 through 29 and 31 through 32,

including, but not limited to, the statements and representations contained in advertising and
telemarketing scripts attached as Exhibits A -l through C, the Powlowsky Defendants and the
Fusco Defendants have represented, directly or indirectly, expressly or by implication, that:
a.

FlexiPrin reduces joint and back pain, inflammation, and stiffness in as
little as two hours;

b.

FlexiPrin rebuilds damaged joints and cartilage; and

c.

FlexiPrin has been clinically proven to:
i.
ii.

69.

Reduce the need for medication in 80% of users;
Reduce joint stiffness in the morning in 100% of users;

iii.

Relieve joint pain in two hours;

iv.

Provide better joint flexibility; and

v.

Rebuild damaged joints and cartilage.

The representations set forth in Paragraph 68 are false or misleading, or, with

respect to the representations set forth in Paragraph 68 a and b, were not substantiated at the time
25
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COUNT III
EXPERT ENDORSERS’ FALSE OR UNSUBSTANTIATED CLAIMS
ABOUT FLEXIPRIN AND COGNIPRIN
72.

Through the means described in Paragraphs 24 through 27, 43 through 44, 49

through 50, and 52, Defendant Jahner, appearing as a medical or expert endorser, has
represented, directly or indirectly, expressly or by implication, that:
a.

FlexiPrin reduces joint pain, inflammation, and stiffness in as little as two
hours;

b.

FlexiPrin rebuilds damaged joints and cartilage;

c.

FlexiPrin has been clinically proven to:
i.

Reduce the need for medication in 80% of users;

ii.

Reduce joint stiffness in the morning in 100% of users; and

iii.

73.

Relieve joint pain in two hours;

d.

CogniPrin reverses mental decline by twelve years;

e.

CogniPrin improves memory by 44 percent;

f.

CogniPrin increases memory in as little as three weeks; and

g.

CogniPrin is clinically proven to improve memory.

Through the means described in Paragraphs 39 through 41, Defendant Minshew,

appearing as a medical or expert endorser, has represented, directly or indirectly, expressly or by
implication, that:
a.

CogniPrin reverses mental decline by twelve years;

b.

CogniPrin improves memory by 44 percent;

c.

CogniPrin increases memory in as little as three weeks; and

d.

CogniPrin is clinically proven to improve memory.
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constitutes a deceptive act or practice and the making of false advertisements in or affecting
commerce, in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52.
COUNT V
DECEPTIVE FORMAT OF RADIO ADVERTISING
79.

Through the means described in Paragraphs 23, 37, 38, and 42, the Powlowsky

Defendants and the Fusco Defendants have represented, directly or indirectly, expressly or by
implication, that the FlexiPrin and CogniPrin radio shows referenced in Exhibits A -l, A-2, D -l,
D-2, E -l, and E-2 were objective news or informational programming.
80.

In fact, the referenced radio programs were not objective news or informational

programming. They were paid commercial advertising. Therefore, the making of the
representation set forth in Paragraph 79 constitutes a deceptive act or practice and the making of
false advertisements in or affecting commerce, in violation of Sections 5(a) and 12 of the FTC
Act, 15 U.S.C. §§ 45(a) and 52.
COUNT VI
FALSE ADVERTISING IN CONNECTION WITH
DEFENDANT JAHNER AS AN ENDORSER
81.

Through the means described in Paragraphs 23 through 28, 42 through 44, and 50

through 52, including, but not limited to the statements and representations contained in radio
advertising and an internet blog, attached as Exhibits A -l, A-2, E -l, E-2, and H, the Powlowsky
Defendants, the Fusco Defendants, and Defendant Jahner have represented, directly or indirectly,
expressly or by implication, that Defendant Jahner was presenting his objective, independent
expert opinions regarding the efficacy of FlexiPrin and CogniPrin.
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expressly or by implication, that they could try FlexiPrin or CogniPrin risk-free with an
unconditional 90-day money-back guarantee.
88.

The representations in Paragraph 87 are false because Defendants required

consumers to pay: the cost of the initial shipment, which was not refundable; the cost of
returning both full and empty bottles of the product; the full cost of FlexiPrin and CogniPrin if
consumers did not follow the undisclosed or inadequately disclosed return and refund policies
described in Paragraphs 57 through 59; and additional charges for inadequately disclosed
continuity shipments of FlexiPrin and CogniPrin.
89.

Therefore, the making of the representation set forth in Paragraph 87 constitutes a

deceptive act or practice in or affecting commerce, in violation of Section 5(a) of the FTC Act,
15 U.S.C. § 45(a).
COUNT IX
MISREPRESENTATION ABOUT THE COGNIPRIN 30-DAY FREE TRIAL OFFER
90.

Through the means described in Paragraphs 45 and 60, the Powlowsky

Defendants have represented to consumers, directly or indirectly, expressly or by implication,
that they could try CogniPrin for 30 days without incurring any financial obligation.
91.

The representation in Paragraph 90 is false because the Powlowsky Defendants

failed to disclose, or did not adequately disclose, that: (a) in order to qualify for the 30-day free
trial, consumers had to accept a 60-day continuity plan that would begin 21 days after placing the
order; and (b) consumers would not receive their products until 7 to 10 days after placing their
orders, thereby giving them 14 days or less to try the product, as described in Paragraph 61.
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customer takes an affirmative action to avoid the charge(s), the date(s) the charge(s) will be
submitted for payment, and the specific steps the customer must take to avoid the charge(s).
16 C.F.R. § 310.3(a)(l)(i), (iii), and (vii).
96.

“Upselling” is defined by the TSR as “soliciting of the purchase of goods or

services following an initial transaction during a single telephone call. The upsell is a separate
telemarketing transaction, not a continuation of the initial transaction.” 16 C.F.R. § 3 10.2(ee).
97.

Additionally, the TSR requires sellers or telemarketers in an internal or external

upsell to disclose truthfully, promptly, and in a clear and conspicuous manner the following
information:
a.

The identity of the seller;

b.

That the purpose of the call is to sell goods or services; and

c.

The nature of the goods or services.

16 C.F.R. § 310.4(d)(1), (2), and (3).
98.

The TSR prohibits sellers and telemarketers from “[c]ausing billing information

to be submitted for payment, directly or indirectly, without the express informed consent of the
customer .. . .” 16 C.F.R. § 310.4(a)(7).
Pursuant to Section 3(c) of the Telemarketing Act, 15 U.S.C. § 6102(c), and Section
18(d)(3) of the FTC Act, 15 U.S.C. § 57a(d)(3), a violation of the TSR constitutes an unfair or
deceptive act or practice in or affecting commerce, in violation of Section 5(a) of the FTC Act,
15 U.S.C. § 45(a).
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feature, including, but not limited to, the fact that the customer’s account will be charged unless
the customer takes an affirmative action to avoid the charge(s), the date(s) the charge(s) will be
submitted for payment, and the specific steps the customer must take to avoid the charge(s).
102.

The Powlowsky Defendants’ and the Fusco Defendants’ acts or practices, as

described in Paragraph 101, are deceptive telemarketing acts or practices that violate the TSR, 16
C.F.R. § 310.3(a)(l)(vii).
COUNT XII
FAILURE TO MAKE REQUIRED ORAL DISCLOSURES
(By Both Plaintiffs)
103.

In numerous instances, in connection with the Powlowsky Defendants’ and the

Fusco Defendants’ efforts to externally “upsell” discount buying clubs and a supplemental health
savings plan, as described in Paragraphs 62 and 63, they fail to disclose promptly and in a clear
and conspicuous manner to consumers the identity of the third-party seller.
104.

The Powlowsky Defendants’ and the Fusco Defendants’ acts or practices, as

described in Paragraph 103, are abusive telemarketing acts or practices that violate the TSR, 16
C.F.R. § 310.4(d)(1).
COUNT XIII
FAILURE TO OBTAIN EXPRESS INFORMED CONSENT
(By Both Plaintiffs)
105.

In numerous instances, in connection with the Powlowsky Defendants’ and the

Fusco Defendants’ efforts to “upsell” discount buying clubs and a supplemental health savings
plan, as described in Paragraphs 62 and 63, the Powlowsky Defendants cause billing information
to be submitted for payment without the express informed consent of the consumer.
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COUNT XIV
EFTA AND REGULATION E
(By Plaintiff FTC)
111.

In numerous instances, the Powlowsky Defendants debit consumers’ bank

accounts on a recurring basis without obtaining a written authorization signed or similarly
authenticated from consumers for preauthorized electronic fund transfers from their accounts,
thereby violating Section 907(a) of EFTA, 15 U.S.C. § 1693e(a), and Section 1005.10(b) of
Regulation E, 12 C.F.R. § 1005.10(b).
112.

In numerous instances, the Powlowsky Defendants debit consumers’ bank

accounts on a recurring basis without providing to the consumer a copy of a written authorization
signed or similarly authenticated by the consumer for preauthorized electronic fund transfers
from the consumer’s account, thereby violating Section 907(a) of EFTA, 15 U.S.C. § 1693e(a),
and Section 1005.10(b) of Regulation E, 12 C.F.R. § 1005.10(b).
113.

By engaging in violations of EFTA and Regulation E as set forth in Paragraphs

112 and 113 the Powlowsky Defendants have engaged in violations of 15 U.S.C. § 1693o(c) and
the FTC Act, 15 U.S.C. §§ 41 et seq.
VIOLATIONS OF MAINE LAW
114.

Section 207 of the Maine UTPA, Me . Rev . Stat . tit. 5, § 207, declares unlawful

“unfair methods of competition and unfair or deceptive acts or practices in the conduct of any
trade or commerce.”
115.

Material misrepresentations or omissions of material fact constitute deceptive acts

or practices prohibited by Section 207 of the UTPA.
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The Powlowsky Defendants’ and the Fusco Defendants’ conduct, as described

herein, is intentional.
COUNT XVI
THE POWLOWSKY DEFENDANTS’ AND THE FUSCO DEFENDANTS’
FALSE OR UNSUBSTANTIATED CLAIMS ABOUT COGNIPRIN
123.

Plaintiff State of Maine incorporates herein by reference all of the allegations

contained in Paragraph 70 of this Complaint.
124.

The representations set forth in Paragraph 70 are false or misleading, or, with

respect to the representations set forth in Paragraph 70 a through c, were not substantiated at the
time the representations were made. Therefore, the making of the representations set forth in
Paragraph 70 constitutes a deceptive act or practice and the making of false advertisements, in or
affecting trade or commerce, in violation of M e . Rev . Stat . tit. 5, § 207.
125.

The Powlowsky Defendants’ and the Fusco Defendants’ conduct, as described

herein, is intentional.
COUNT XVII
EXPERT ENDORSERS’ FALSE OR UNSUBSTANTIATED CLAIMS
ABOUT FLEXIPRIN AND COGNIPRIN
126.

Plaintiff State of Maine incorporates herein by reference all of the allegations

contained in Paragraphs 72 and 73 of this Complaint.
127.

The representations set forth in Paragraphs 72 and 73 are false or misleading, or,

with respect to the representations set forth in Paragraph 72 a, b, and d through f, and Paragraph
73 a through c, were not substantiated at the time the representations were made. Moreover,
Defendants Jahner and Minshew did not exercise their purported expertise in the form of an
examination or testing of the products. Their purported scientific proof for the representations
set forth in Paragraphs 72 and 73 was not the result of an examination or testing at least as
39

Case l:1 7 -cv-0 0 0 6 7 -N T

D ocum ent 1

Filed 02/22/17

Page 41 of 46

PagelD #: 41

false advertisements, in or affecting trade or commerce, in violation of M e . Rev . Stat . tit. 5,
§207.
135.

The conduct of the Powlowsky Defendants and the Fusco Defendants, as

described herein, is intentional.
COUNT XX
FALSE ADVERTISING IN CONNECTION WITH
DEFENDANT JAHNER AS AN ENDORSER
136.

Plaintiff State of Maine incorporates herein by reference all of the allegations

contained in Paragraph 81.
137.

The representations set forth in Paragraph 81 are false. In fact, the Powlowsky

Defendants made royalty payments to Defendant Jahner to appear as an expert endorser for
FlexiPrin and CogniPrin.
138.

Therefore, the making of the representations set forth in Paragraph 81 constitutes

a deceptive act or practice and the making of false advertisements, in or affecting trade or
commerce, in violation of M e . Rev . Stat . tit. 5, § 207.
139.

The conduct of the Powlowsky Defendants, the Fusco Defendants, and Defendant

Jahner, as described herein, is intentional.
COUNT XXI
MISREPRESENTATION OF DEFENDANT MINSHEW’S EXPERTISE
140.

Plaintiff State of Maine incorporates herein by reference all of the allegations

contained in Paragraph 84 of this Complaint.
141.

The representation set forth in Paragraph 84 is false. In fact, Defendant Minshew,

a/k/a Samuel Brant, is not an expert in neurology, brain science, or cognitive decline
142.

Therefore, the making o f the representation set forth in Paragraph 84 constitutes a

41

Case l:1 7 -cv-0 0 0 6 7 -N T

149.

D ocum ent 1

Filed 02/22/17

Page 43 of 46

PagelD #: 43

The representation in Paragraph 90 is false because the Powlowsky Defendants

failed to disclose, or did not adequately disclose, that: (a) in order to qualify for the 30-day free
trial, consumers had to accept a 60-day continuity plan that would begin 21 days after placing the
order; and (b) consumers would not receive their products until 7 to 10 days after placing their
orders, thereby giving them 14 days or less to try the product, as described in Paragraph 61.
150.

Therefore, the making of the representation set forth in Paragraph 90 constitutes a

deceptive act or practice in or affecting trade or commerce, in violation of M e . Rev . Stat. tit. 5,
§ 207 and M e . Rev . Stat . tit. 10, § 1210.
151.

The conduct of the Powlowsky Defendants, as described herein, is intentional.
CONSUMER INJURY

152.

Consumers have suffered and will continue to suffer substantial injury as a result

of Defendants’ violations of the FTC Act, the TSR, the EFTA, the Maine UTPA, and M e . Rev .
S tat . tit. 10, § 1210. In addition, Defendants have been unjustly enriched as a result of their

unlawful acts or practices. Absent injunctive relief by this Court, Defendants are likely to
continue to injure consumers, reap unjust enrichment, and harm the public interest.
THE COURT’S POWER TO GRANT RELIEF
153.

Section 13(b) of the FTC Act, 15 U.S.C. § 53(b), empowers this Court to grant

injunctive and such other relief as the Court may deem appropriate to halt and redress violations
of any provision of law enforced by the FTC, including the Telemarketing Act, the TSR, the
EFTA, and Reg. E. The Court, in the exercise of its equitable jurisdiction, may award ancillary
relief, including rescission or reformation of contracts, restitution, the refund of monies paid, and
the disgorgement of ill-gotten monies, to prevent and remedy any violation of any provision of
law enforced by the FTC.
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not limited to, rescission or reformation of contracts, restitution, the refund of
monies paid, and the disgorgement of ill-gotten monies; and
C.

Award Plaintiff FTC the costs of bringing this action, as well as such other and
additional relief as the Court may determine to be just and proper.
MAINE PRAYER FOR RELIEF

Wherefore, Plaintiff State of Maine, pursuant to Section 4(a) of the Telemarketing Act,
15 U.S.C. § 6103(a), Section 209 of the Maine UTPA, M e . Rev . Stat . tit. 5, § 209, and the
Court’s own equitable powers, requests that the Court:
A.

Enter an order declaring Defendants’ above-described conduct to be in violation
of the TSR and the Maine UTPA, § 207, and to be intentional violations pursuant
to the Maine UTPA, § 209;

B.

Enter a permanent injunction to prevent future violations of the TSR and the
Maine UTPA by Defendants;

C.

Award such relief as the Court finds necessary to redress injury to consumers
resulting from Defendants’ violations of the TSR and the Maine UTPA, including
but not limited to, rescission or reformation of contracts, restitution, the refund of
monies paid, and the disgorgement of ill-gotten monies;

D.

Adjudge civil penalties of not more than ten thousand dollars ($10,000) for each
intentional violation of the Maine UTPA pursuant to M e . Rev . Stat . tit. 5, § 209;
and

45

